<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use - Christelle, K - 2022 | Cochrane Library</title> <meta content="Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use - Christelle, K - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006034.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use - Christelle, K - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006034.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006034.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use" name="citation_title"/> <meta content="Karen Christelle" name="citation_author"/> <meta content="Universiti Sains Malaysia" name="citation_author_institution"/> <meta content="Mohd N Norhayati" name="citation_author"/> <meta content="Universiti Sains Malaysia" name="citation_author_institution"/> <meta content="hayatikk@usm.my" name="citation_author_email"/> <meta content="Sharifah Halimah Jaafar" name="citation_author"/> <meta content="Regency Specialist Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006034.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/08/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006034.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006034.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006034.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [therapeutic use]; Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Dysmenorrhea [drug therapy, prevention &amp; control]; Ibuprofen [therapeutic use]; *Intrauterine Devices, Medicated [adverse effects]; Mefenamic Acid [therapeutic use]; *Menorrhagia [drug therapy, etiology, prevention &amp; control]; Naproxen [therapeutic use]; Thiamine [therapeutic use]; *Tranexamic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006034.pub3&amp;doi=10.1002/14651858.CD006034.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006034\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006034\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006034.pub3",title:"Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine\\u2010device use",firstPublishedDate:"Aug 26, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Fertility Regulation Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006034.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006034.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006034.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006034.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006034.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006034.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006034.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006034.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006034.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006034.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4596 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006034.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/appendices#CD006034-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/supinfo/CD006034StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/supinfo/CD006034StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information#CD006034-cr-0004">Karen Christelle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information#CD006034-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Mohd N Norhayati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information#CD006034-cr-0006">Sharifah Halimah Jaafar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information/en#CD006034-sec-0129">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 August 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006034.pub3">https://doi.org/10.1002/14651858.CD006034.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006034-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006034-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006034-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006034-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006034-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006034-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006034-abs-0001" lang="en"> <section id="CD006034-sec-0001"> <h3 class="title" id="CD006034-sec-0001">Background</h3> <p>Heavy menstrual bleeding and pain are common reasons women discontinue intrauterine device (IUD) use. Copper IUD (Cu IUD) users tend to experience increased menstrual bleeding, whereas levonorgestrel IUD (LNG IUD) users tend to have irregular menstruation. Medical therapies used to reduce heavy menstrual bleeding or pain associated with Cu and LNG IUD use include non‐steroidal anti‐inflammatory drugs (NSAIDs), anti‐fibrinolytics and paracetamol. We analysed treatment and prevention interventions separately because the expected outcomes for treatment and prevention interventions differ. We did not combine different drug classes in the analysis as they have different mechanisms of action. This is an update of a review originally on NSAIDs. The review scope has been widened to include all interventions for treatment or prevention of heavy menstrual bleeding or pain associated with IUD use. </p> </section> <section id="CD006034-sec-0002"> <h3 class="title" id="CD006034-sec-0002">Objectives</h3> <p>To evaluate all randomized controlled trials (RCTs) that have assessed strategies for treatment and prevention of heavy menstrual bleeding or pain associated with IUD use, for example, pharmacotherapy and alternative therapies. </p> </section> <section id="CD006034-sec-0003"> <h3 class="title" id="CD006034-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase and CINAHL to January 2021.</p> </section> <section id="CD006034-sec-0004"> <h3 class="title" id="CD006034-sec-0004">Selection criteria</h3> <p>We included RCTs in any language that tested strategies for treatment or prevention of heavy menstrual bleeding or pain associated with IUD (Cu IUD, LNG IUD or other IUD) use. The comparison could be no intervention, placebo or another active intervention. </p> </section> <section id="CD006034-sec-0005"> <h3 class="title" id="CD006034-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion and risk of bias, and extracted data. Primary outcomes were volume of menstrual blood loss, duration of menstruation and painful menstruation. We used a random‐effects model in all meta‐analyses. Review authors assessed the certainty of evidence using GRADE. </p> </section> <section id="CD006034-sec-0006"> <h3 class="title" id="CD006034-sec-0006">Main results</h3> <p>This review includes 21 trials involving 3689 participants from middle‐ and high‐income countries. Women were 18 to 45 years old and either already using an IUD or had just had one placed for contraception. The included trials examined NSAIDs and other interventions. Eleven were treatment trials, of these seven were on users of the Cu IUD, one on LNG IUD and three on an unknown type. Ten were prevention trials, six focused on Cu IUD users, and four on LNG IUD users. Sixteen trials had high risk of detection bias due to subjective assessment of pain and bleeding. </p> <p><b>Treatment of heavy menstrual bleeding</b> </p> <p><b><i>Cu IUD</i> </b> </p> <p>Vitamin B1 resulted in fewer pads used per day (mean difference (MD) −7.00, 95% confidence interval (CI) −8.50 to −5.50) and fewer bleeding days (MD −2.00, 95% CI –2.38 to −1.62; 1 trial; 110 women; low‐certainty evidence) compared to placebo. The evidence is very uncertain about the effect of naproxen on the volume of menstruation compared to placebo (odds ratio (OR) 0.09, 95% CI 0.00 to 1.78; 1 trial, 40 women; very low‐certainty evidence). </p> <p>Treatment with mefenamic acid resulted in less volume of blood loss compared to tranexamic acid (MD −64.26, 95% CI −105.65 to −22.87; 1 trial, 94 women; low‐certainty evidence). However, there was no difference in duration of bleeding with treatment of mefenamic acid or tranexamic acid (MD 0.08 days, 95% CI −0.27 to 0.42, 2 trials, 152 women; low‐certainty evidence). </p> <p><b><i>LNG IUD</i> </b> </p> <p>The use of ulipristal acetate in LNG IUD may not reduce the number of bleeding days in 90 days in comparison to placebo (MD −9.30 days, 95% CI −26.76 to 8.16; 1 trial, 24 women; low‐certainty evidence). </p> <p><b><i>Unknown IUD type</i> </b> </p> <p>Mefenamic acid may not reduce volume of bleeding compared to Vitex agnus measured by pictorial blood assessment chart (MD −2.40, 95% CI −13.77 to 8.97; 1 trial; 84 women; low‐certainty evidence). </p> <p><b>Treatment of pain</b> </p> <p><b><i>Cu IUD</i> </b> </p> <p>Treatment with tranexamic acid and sodium diclofenac may result in little or no difference in the occurrence of pain (OR 1.00, 95% CI 0.06 to 17.25; 1 trial, 38 women; very low‐certainty evidence). </p> <p><b><i>Unknown IUD type</i> </b> </p> <p>Naproxen may reduce pain (MD 4.10, 95% CI 0.91 to 7.29; 1 trial, 33 women; low‐certainty evidence). </p> <p><b>Prevention of heavy menstrual bleeding</b> </p> <p><b><i>Cu IUD</i> </b> </p> <p>We found very low‐certainty evidence that tolfenamic acid may prevent heavy bleeding compared to placebo (OR 0.54, 95% CI 0.34 to 0.85; 1 trial, 310 women). There was no difference between ibuprofen and placebo in blood volume reduction (MD −14.11, 95% CI −36.04 to 7.82) and duration of bleeding (MD −0.2 days, 95% CI −1.40 to 1.0; 1 trial, 28 women, low‐certainty evidence). </p> <p>Aspirin may not prevent heavy bleeding in comparison to paracetamol (MD −0.30, 95% CI −26.16 to 25.56; 1 trial, 20 women; very low‐certainty evidence). </p> <p><b><i>LNG IUD</i> </b> </p> <p>Ulipristal acetate may increase the percentage of bleeding days compared to placebo (MD 9.50, 95% CI 1.48 to 17.52; 1 trial, 118 women; low‐certainty evidence). There were insufficient data for analysis in a single trial comparing mifepristone and vitamin B. </p> <p>There were insufficient data for analysis in the single trial comparing tranexamic acid and mefenamic acid and in another trial comparing naproxen with estradiol. </p> <p><b>Prevention of pain</b> </p> <p><b><i>Cu IUD</i> </b> </p> <p>There was low‐certainty evidence that tolfenamic acid may not be effective to prevent painful menstruation compared to placebo (OR 0.71, 95% CI 0.44 to 1.14; 1 trial, 310 women). Ibuprofen may not reduce menstrual cramps compared to placebo (OR 1.00, 95% CI 0.11 to 8.95; 1 trial, 20 women, low‐certainty evidence). </p> </section> <section id="CD006034-sec-0007"> <h3 class="title" id="CD006034-sec-0007">Authors' conclusions</h3> <p>Findings from this review should be interpreted with caution due to low‐ and very low‐certainty evidence. Included trials were limited; the majority of the evidence was derived from single trials with few participants. Further research requires larger trials and improved trial reporting. The use of vitamin B1 and mefenamic acid to treat heavy menstruation and tolfenamic acid to prevent heavy menstruation associated with Cu IUD should be investigated. More trials are needed to generate evidence for the treatment and prevention of heavy and painful menstruation associated with LNG IUD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006034-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006034-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006034-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006034-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006034-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006034-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006034-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006034-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006034-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006034-abs-0002" lang="en"> <h3>Medications for heavy menstrual bleeding and pain related to intrauterine devices used for birth control </h3> <p><b>Background</b> </p> <p>Heavy menstrual bleeding and cramping are the most common reasons why women stop using an intrauterine device (IUD) for birth control. We reviewed studies to find out whether pain relief or other medicines, or other methods could reduce bleeding and pain related to IUD use. </p> <p><b>Study characteristics</b> </p> <p>The evidence is up‐to‐date to January 2021. We included studies that investigated the treatment or prevention of heavy menstrual bleeding or pain related to IUD use. The treatment could be compared with another medicine, no treatment or a placebo (dummy medicine). </p> <p><b>Key results</b> </p> <p>This review includes 21 studies with 3689 women. Eleven studies investigated treatment, while 10 looked at prevention of heavy bleeding and pain. Most of the evidence was obtained from single studies with few participants. We have little to no confidence in the results of the studies. Our confidence is limited because some studies involved only a few people, had varied interventions or had no clear reports on how the study was conducted. </p> <p><b>Treatment of heavy menstrual bleeding</b> </p> <p><b>Copper IUD</b> </p> <p>Vitamin B1 may reduce the duration of bleeding, number of spotting days and number of pads used per day while. Mefenamic acid may reduce the volume but not the duration of bleeding when compared to tranexamic acid. Naproxen may not reduce the amount of menstrual bleeding associated with copper IUD. </p> <p><b>Levonorgestrel IUD</b> </p> <p>Among levonorgestrel IUD users, ulipristal may not reduce the duration of bleeding.</p> <p><b>Unknown IUD type</b> </p> <p>In one study with an unknown IUD type, we found that mefenamic acid may not reduce the volume of menstrual bleeding. </p> <p><b>Treatment of painful menstruation</b> </p> <p><b>Copper IUD</b> </p> <p>Treatment with tranexamic acid and sodium diclofenac may not reduce the occurrence of painful menstruation associated with copper IUD. </p> <p><b>Unknown IUD type</b> </p> <p>Naproxen may reduce pain associated with an unknown IUD type</p> <p><b>Prevention of heavy menstrual bleeding</b> </p> <p><b>Copper IUD</b> </p> <p>Tolfenamic acid may prevent heavy menstrual bleeding while ibuprofen made little to no difference to the volume and duration of menstrual bleeding when compared to placebo. Aspirin in comparison to paracetamol, may not prevent the occurrence of heavy menstrual bleeding. </p> <p><b>Levonorgestrel IUD</b> </p> <p>Studies on tranexamic acid, estradiol, naproxen and mifepristone could not tell us whether they prevented heavy menstrual bleeding associated with levonorgestrel IUD use. </p> <p><b>Prevention of painful menstruation</b> </p> <p><b>Copper IUD</b> </p> <p>Tolfenamic acid and ibuprofen may not be effective to prevent painful menstruation compared with placebo. </p> <p><b>Authors' conclusions</b> </p> <p>Heavy menstrual bleeding among copper IUD users may be treated with vitamin B and mefenamic acid while tranexamic acid and diclofenac may not alleviate painful menstruation. As for levonorgestrel IUD users, ulipristal may not reduce or prevent heavy menstrual bleeding. Tolfenamic acid may prevent heavy menstrual bleeding but not pain associated with levonorgestrel IUD. Our confidence in the evidence is low to very low. More studies are needed in the future to generate higher‐quality evidence regarding effective medicines to treat and prevent heavy menstrual bleeding and painful menstruation associated with IUD use. Evidence from further studies is likely to change our results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006034-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006034-sec-0116"></div> <h3 class="title" id="CD006034-sec-0117">Implications for practice</h3> <section id="CD006034-sec-0117"> <p>Even though 210 trials met the criteria for inclusion, the shortcomings in several of the trials must be emphasized. The trials were predominantly small and for numerous outcomes the results were obtained from only one trial. The most effective non‐steroidal anti‐inflammatory drug (NSAID) and regimen is still uncertain. If treatment with NSAID did not deliver the anticipated improvement in bleeding, tranexamic acid may well be considered. Our low‐certainty evidence also suggests that tolfenamic acid may be used prophylactically to reduce heavy menstrual bleeding but not pain with Cu IUD use. Evidence on the use of prophylactic ibuprofen and aspirin for CDB‐2914 (ulipristal acetate) within the first six months of Cu IUD insertion to reduce heavy menstrual bleeding and pain was limited and more research is needed to inform clinical practice. CDB‐2914 (ulipristal acetate) may also not be effective for the prevention of levonorgestrel intrauterine device (LNG IUD)‐associated heavy menstrual bleeding. Women initiated on NSAIDs or tranexamic acid should be made aware of the potential side effects, such as gastrointestinal discomfort and headache, as the use of tranexamic acid increased the odds for the occurrence these side effects in comparison to sodium diclofenac. Further large trials should be conducted over a longer duration to establish their effectiveness and safety. </p> </section> <h3 class="title" id="CD006034-sec-0118">Implications for research</h3> <section id="CD006034-sec-0118"> <p>As evidence was scarce for the majority of analyses in this review, larger, high‐quality randomized controlled trials (RCTs) are essential to establish the effectiveness as well as the optimum dose and regimen of mefenamic acid and tranexamic acid to reduce heavy menstrual bleeding, naproxen to reduce pain, along with prophylactic tolfenamic acid for heavy menstrual bleeding associated with Cu IUD use. Future trials should also collect comprehensive data on side effects and potential adverse effects. Currently, there are no trials investigating the use of other NSAIDs such as celecoxib and etoricoxib for the prevention and treatment of heavy menstrual bleeding or pain, or both, associated with IUD use. Future RCTs can be designed to assess the effectiveness and safety of these NSAIDs. Trials should also investigate the use of NSAIDs, tranexamic acid or other interventions for the treatment and prevention of heavy bleeding and pain associated with LNG IUD. As intrauterine devices (IUDs) are used as long‐term contraceptives and can be in place for an average of five years, future RCTs should assess their interventions throughout a similar duration of follow‐up. Longer follow‐up may also facilitate better assessment of adverse events. </p> <p>In addition, the National Institute for Health and Care Excellence (NICE) in the UK has recommended that any intervention for heavy menstrual bleeding should also be intended to enhance quality of life (<a href="./references#CD006034-bbs2-0066" title="NICE. Heavy menstrual bleeding: assessment and management. www.nice.org.uk/guidance/ng882018.">NICE 2018</a>). However, no trials in this review assessed the effect of interventions on quality of life. Forthcoming trials should include these measures using validated questionnaires such as the Menstrual Bleeding Questionnaire (<a href="./references#CD006034-bbs2-0063" title="MattesonKA , ScottDM , RakerCA , ClarkMA . The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. International Journal of Obstetrics and Gynaecology2015;122(5):681-9.">Matteson 2015</a>), to adequately represent women’s experiences and incorporate these measures as primary outcomes rather than solely quantifying the amount of blood loss objectively or semi‐objectively. </p> <p>It is of utmost importance that these upcoming trials report in detail the methods used, to allow comprehensive risk of bias assessment. Full results should also be presented with a summary of effect measures to ease analysis. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006034-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006034-sec-0008"></div> <div class="table" id="CD006034-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Interventions (vitamin B1, mefenamic acid, tranexamic acid) compared to placebo or active comparators (desmopressin, sodium diclofenac, flavonoids) for the treatment of heavy menstrual bleeding associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interventions versus comparisons</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Vitamin B1 vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Number of pads (diary record)</p> <p>Follow‐up: 1 month after completion of intervention for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of pads was <b>19 pads</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>7 pads fewer</b><br/>(8.5 fewer to 5.5 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days</p> <p>(diary record)</p> <p> </p> <p>Follow‐up: 1 month after completion of intervention for three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of bleeding was <b>8</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>2 days fewer</b><br/>(2.38 fewer to 1.62 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mefenamic acid vs tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Volume blood loss (pictorial chart in mL)</p> <p> </p> <p>Follow‐up: after 3rd month of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean volume of menstrual blood loss was <b>160 mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>64.26 mL lower</b><br/>(105.65 lower to 22.87 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days (menstrual record)</p> <p> </p> <p>Follow‐up: after 3rd month of intervention</p> <p>Recorded on daily diary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of bleeding days was <b>3.5 to 6.4 days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.08 days more</b><br/>(0.27 fewer to 0.42 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mefenamic acid vs desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Mean reduction of PBAC score</p> <p>Follow‐up: after 3rd month of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>The mean reduction of PBAC score was 40.5% in desmopressin and 45.7% in mefenamic acid </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>b,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs sodium diclofenac</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Volume of blood loss (alkaline hematin method)</p> <p>Follow‐up: each intervention cycle (cross‐over) for 5 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss was <b>102</b>mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>42.7mL lower</b><br/>(73.33 lower to 12.07 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>c,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p> </p> <p>Follow‐up: each intervention cycle (cross‐over) for 5 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of bleeding was <b>5.1</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0 days </b><br/>(0.62 lower to 0.62 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>b,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastrointestinal disturbances (diarrhoea, lower abdominal pain), headache and sweating </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>316 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>684 per 1000 (356 to 895)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 4.69</p> <p>(1.2 to 18.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>b,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs flavonoids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>PBAC score</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score was <b>125</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>32 lower</b><br/>(39.84 lower to 24.16 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Number of pads per day</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of pads was <b>3</b> pads per day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.5 pads lower</b><br/>(0.91 lower to 0.09 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of bleed days was <b>6.8</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.4 days lower</b><br/>(1.93 lower to 0.87 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: headache </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 per 1000 (33 to 268)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.58 (0.18 to 1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: vomiting </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000 (33 to 268)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74 (0.25 to 2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs active comparators (mefenamic acid, flavonoid, sodium diclofenac)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days</p> <p>Follow‐up: 2‐5 menstrual cycles</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of bleeding days was <b>5.1 to 6.8</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.27 days lower</b><br/>(1.14 lower to 0.6 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>f,h</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>PBAC:</b> pictorial blood assessment chart; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to unclear risk of selection bias.<br/><sup>b</sup>Downgraded one level for imprecision as effects were measured by one trial.<br/><sup>c</sup>Downgraded two levels for imprecision as effects were measured by one trial and the confidence interval was wide.<br/><sup>d</sup>Downgraded two levels due to unclear risk of selection bias and high risk of detection bias.<br/><sup>e</sup>Downgraded two levels due to high risk of performance bias and detection bias.<br/><sup>f</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias and high risk of detection bias.<br/><sup>g</sup>Downgraded one level due to high risk of detection bias.<br/><sup>h</sup>Downgraded one level for inconsistency due to high statistical heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ulipristal acetate compared to placebo for the treatment of heavy menstrual bleeding associated with LNG IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interventions vs comparisons</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ulipristal acetate vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Total bleeding in 90 days (bleeding calendar)</p> <p>Follow‐up: 30, 60 and 90 days after treatment initiation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean total of bleeding days in 90 days was <b>29.8 to 39.1</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>9.3 days lower</b><br/>(26.76 lower to 8.16 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to high risk of detection bias.<br/><sup>b</sup>Downgraded two levels for imprecision as effects were only measured from one trial with small number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mefanamic acid compared to Vitex agnus for the treatment of heavy menstrual bleeding associated with unknown IUD type</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interventions vs comparisons</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Mefenamic acid vs Vitex agnus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>PBAC score</p> <p>Follow‐up: monthly for 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score was <b>89.7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.4 lower</b><br/>(13.77 lower to 8.97 higher </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: nausea </p> <p>Follow‐up: monthly for 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> (1 to 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>OR 1.00 (0.06 to 16.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: abdominal pain </p> <p>Follow‐up: monthly for 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (0 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>OR 0.33 (0.01 to 8.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>c</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>PBAC:</b> pictorial blood assessment chart; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to unclear reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as effects were measured by only one trial.<br/><sup>c</sup>Downgraded two levels for imprecision as effects were measured from only one trial and confidence interval was wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tranexamic acid compared to sodium diclofenac for the treatment of pain associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs sodium diclofenac</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pelvic pain</b> </p> <p>Follow‐up: each intervention cycle (cross over) for 5 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 per</b> 1000<br/>(3 to 489) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.06 to 17.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias and high risk of detection bias.<br/><sup>b</sup>Downgraded one level for imprecision as effect measures were from one small trial. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Naproxen compared to placebo for the treatment of pain associated with unknown IUD type</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naproxen vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall pain relief score</b> (4‐point scale) </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean overall pain relief score was <b>7.9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>4.1 higher</b><br/>(0.91 higher to 7.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily pain relief score</b> (6‐point scale) </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean daily pain relief score was <b>10.8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.1 higher</b><br/>(0.27 higher to 5.93 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for additional analgesia</b> (self‐recorded) </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>116 per</b> 1000<br/>(22 to 450) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.29</b><br/>(0.05 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastrointestinal symptoms </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> (9 to 557) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.11 (0.18 to 25.17)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias as well as high risk of detection bias.<br/><sup>b</sup>Downgraded one level for imprecision as effect measures were from one small trial. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) compared to placebo or active comparators (paracetamol, tranexamic acid) for the prevention of heavy menstrual bleeding associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ibuprofen vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> (alkaline hematin method) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss was <b>44.7 to 109.2 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 14.11 mL lower</b><br/>(36.04 lower to 7.82 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> (menstrual diary) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of bleed was <b>6.4</b> days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.2 days lower</b><br/>(0.14 lower to 1 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> eye and mouth swelling, stomach cramps, fatigue, irritability (diary record) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> (20 to 271) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.15</b> (0.5 to 9.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tolfenamic acid vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Menstruation "more abundant than normal"</p> <p>(questionnaire)</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per</b> 1000<br/>(396 to 621) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b><br/>(0.34 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> dyspepsia, diarrhoea, headache, fatigue </p> <p>(questionnaire)</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per</b> 1000<br/>(20 to 200) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.48</b><br/>(0.14 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aspirin vs paracetamol</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> (alkaline hematin method) </p> <p>Follow‐up: 3 cycles</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss was <b>49.5 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.3mL lower</b><br/>(26.16 lower to 25.56 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>2 g tranexamic acid vs 1 g tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>% occurrence of heavy menstrual bleeding (alkaline hematin method)</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 g tranexamic acid: 20</p> <p>1 g tranexamic acid: 11.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>% occurrence heavy menstrual bleeding (PBAC score)</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 g tranexamic acid: 26.79</p> <p>1 g tranexamic acid: 45.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>PBAC:</b> pictorial blood assessment chart; <b>RCT:</b> randomized controlled trial; vs: versus </p> <p><sup>a</sup>Downgraded one level due to unclear risk of selection and reporting bias. <br/><sup>b</sup>Downgraded two levels due to substantially wide confidence interval and effects measures from only one small trial. <br/><sup>c</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias as well as high risk of detection bias. <br/><sup>d</sup>Downgraded one level for imprecision as effect measures were from one trial. <br/><sup>e</sup>Downgraded two levels due to unclear risk of selection, performance, attrition and reporting bias as well as high risk of detection bias. <br/><sup>f</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias as well as high risk of other sources of bias (4 out of 10 women on intrauterine devices had prior to intervention, prolonged bleeding time, increased capillary fragility and/or a history of bleeding tendencies). <br/><sup>g</sup>Downgraded two levels due to unclear risk of selection and performance bias, high risk of detection bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Interventions (ulipristal acetate, tranexamic acid, mifepristone, naproxen) compared placebo or active comparators (mefenamic acid, vitamin B, estradiol) for the prevention of heavy menstrual bleeding associated with LNG IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ulipristal acetate vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage days bleeding or spotting</b> (questionnaire) </p> <p>Follow‐up: 1, 3 and 6 months after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean percentage days bleeding or spotting was 20.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.5% higher (1.48 higher to 17.52 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs mefenamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Median number of bleed days (diary)</p> <p>Follow‐up: 90 days of study assessment followed by 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid: 8</p> <p>Mefenamic acid: 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastrointestinal disorders, headache, breast tenderness, musculoskeletal disorders </p> <p>Follow‐up: 90 days of study assessment followed by 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>468 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>468 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00 (0.49 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mifepristone vs vitamin B</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual blood loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>% spotting and bleeding days</p> <p>Follow‐up: 1, 3 and 6 months after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mifepristone: fewer women reported bleeding or spotting. Fewer days with normal or heavy intensity bleeding </p> <p>Vitamin B: more bleeding or spotting days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naproxen vs estradiol</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual blood loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Median number of bleeding and spotting days (diary)</p> <p>Follow‐up: every 4 weeks for 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naproxen: 27.5</p> <p>Estradiol: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastroesophageal reflux </p> <p>Follow‐up: every 4 weeks for 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.22 (0.13 to 81.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,e</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level for imprecision as effects were measured from one trial.<br/><sup>b</sup>Downgraded one level due to unclear risk of performance bias.<br/><sup>c</sup>Downgraded one level due to high risk of detection bias<br/><sup>d</sup>Downgraded two levels due to high risk of detection bias and unclear risk of performance bias.<br/><sup>e</sup>Downgraded two levels due to high risk of performance bias and detection bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006034-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Interventions (ibuprofen, tolfenamic acid) compared to placebo for the prevention of pain associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ibuprofen vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in painful menstruation</p> <p>Follow‐up: end of 1st, 2nd and 3rd months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>200 per</b> 1000<br/>(27 to 691) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.11 to 8.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tolfenamic acid vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstruation "more painful than normal"</p> <p>Follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>310 per</b> 1000<br/>(217 to 476) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.71</b><br/>(0.44 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>c,d</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as effect measures were from one relatively small trial.<br/><sup>c</sup>Downgraded one level for imprecision as effect measures were from one trial.<br/><sup>d</sup>Downgraded two levels due to unclear risk of selection, performance, attrition and reporting bias as well as high risk of detection bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006034-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006034-sec-0009"></div> <p>The intrauterine device (IUD) is one of the most commonly used methods of reversible contraception worldwide, accounting for 17% of contraceptive use. In 2019, it was used by 159 million women worldwide, up from 133 million women in 1994 (<a href="./references#CD006034-bbs2-0071" title="United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet. www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf.">United Nations 2019</a>). The estimated prevalence of IUD use among women of reproductive age (15 to 49 years) in 2019 was 10.7% in Asia, 8.1% in Europe and 4.6% in Latin America and the Caribbean. The highest prevalence of IUD use in 2019 is in the Democratic People’s Republic of Korea (46.9%) and Uzbekistan (36.9%). Among women of reproductive age, IUDs are used by 151 million married women (20%) in contrast to eight million (6%) unmarried women (<a href="./references#CD006034-bbs2-0071" title="United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet. www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf.">United Nations 2019</a>). </p> <p>Two types of IUD are commonly available: copper‐containing IUDs (Cu IUD) and levonorgestrel‐releasing IUDs (LNG IUD). Adolescent and adult women who desire a highly effective contraceptive method, which is long term and reversible, are eligible for IUD use (<a href="./references#CD006034-bbs2-0046" title="FrancisJK , GoldMA . Long-acting reversible contraception for adolescents: a review. JAMA Pediatrics2017;171:694-701.">Francis 2017</a>). IUD use has no restrictions for women who may have co‐morbidities including but not limited to benign ovarian tumours, breast disease, cervical cancer, cirrhosis, history of deep vein thrombosis, diabetes mellitus, epilepsy, migraine, hypertension, ischaemic heart disease, inflammatory bowel disease, multiple sclerosis, obesity, ovarian cancer, active smoking, thyroid disorders, tuberculosis and valvular heart disease (<a href="./references#CD006034-bbs2-0047" title="GaffieldML , KiarieJ . WHO medical eligibility criteria update. Contraception2016;94:193-4.">Gaffield 2016</a>; <a href="./references#CD006034-bbs2-0070" title="TepperNK , CurtisKM , JatlaouiTC , WhitemanMK . Updated guidance for safe and effective use of contraception. Journal of Women's Health.2016;25:1097-101.">Tepper 2016</a>). </p> <p>Benefits of IUDs include highly effective pregnancy prevention. IUDs are long‐acting and rapidly reversible, with few side effects, few contraindications, reduced risk of cervical and ovarian cancer and do not require regular adherence to maintain their effectiveness (<a href="./references#CD006034-bbs2-0043" title="CortessisVK , BarrettM , Brown WadeN , EnebishT , PerrigoJL , et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstetrics and Gynecology2017;130(6):1226-36.">Cortessis 2017</a>; <a href="./references#CD006034-bbs2-0051" title="HeinemannK , ReedS , MoehnerS , MinhTD . Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European active surveillance study for intrauterine devices. Contraception2015;91(4):280-3.">Heinemann 2015</a>; <a href="./references#CD006034-bbs2-0072" title="World Health Organization. Medical eligibility criteria for contraceptive use. www.who.int/publications/i/item/9789241549158.">WHO 2015</a>). However, despite their many benefits, IUD use is also associated with side effects such as heavier menstrual bleeding, prolonged or unscheduled bleeding, spotting, amenorrhoea and cramping (<a href="./references#CD006034-bbs2-0041" title="Bayer HealthCare Pharmaceuticals. Mirena: highlights of prescribing information. labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf2017.">Bayer 2017</a>). These side effects contribute to fear among women wanting to initiate IUD use as well as discontinuation among existing IUD users, as these effects are disturbing and affect quality of life (<a href="./references#CD006034-bbs2-0045" title="DiedrichJT , DesaiS , ZhaoQ , SecuraG , MaddenT , PeipertJF . Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. American Journal of Obstetrics and Gynecology2014;212(1):50.e1-8.">Diedrich 2015</a>). </p> <section id="CD006034-sec-0010"> <h3 class="title" id="CD006034-sec-0010">Description of the condition</h3> <p>Use of IUDs is associated with heavy menstrual bleeding and pain and these are the most commonly reported reasons for IUD removal within the first six months after insertion (<a href="./references#CD006034-bbs2-0026" title="GrunlohDS , CasnerT , SecuraG , PeipertJF , MaddenT . Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstetrics and Gynecology2013;122(6):1214-21. ">Grunloh 2013</a>). Heavy menstrual bleeding is defined based on a woman’s perception of increased daily or total menstrual volume or flow regardless of the duration, frequency and regularity (<a href="./references#CD006034-bbs2-0066" title="NICE. Heavy menstrual bleeding: assessment and management. www.nice.org.uk/guidance/ng882018.">NICE 2018</a>). This definition is subjective but a volume that impedes a woman’s physical, social, emotional or material quality of life is truly heavy. </p> <p>Previously, heavy menstrual bleeding was defined as a menstrual blood loss of more than 80 mL. However, in 2011, the International Federation of Gynaecology and Obstetrics (FIGO) developed new definitions and terminology for abnormal uterine bleeding symptoms as well as a new classification of underlying causes of abnormal uterine bleeding in the reproductive years (<a href="./references#CD006034-bbs2-0064" title="MunroMG , CritchleyHO , BroderMS , FraserIS . FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology &amp; Obstetrics2011;113:3-13.">Munro 2011</a>). </p> <p>Normal menstruation is defined as a frequency of 24 to 38 days, regularity of seven to nine days or less, duration of eight days or less and a subjective clinical definition of volume, which does not interfere with a woman’s physical, social, emotional or material quality of life. Research definition for normal volume is 80 mL vaginal blood loss per cycle or less. Any symptomatic variation from normal menstruation is thus, abnormal uterine bleeding (<a href="./references#CD006034-bbs2-0064" title="MunroMG , CritchleyHO , BroderMS , FraserIS . FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology &amp; Obstetrics2011;113:3-13.">Munro 2011</a>; <a href="./references#CD006034-bbs2-0066" title="NICE. Heavy menstrual bleeding: assessment and management. www.nice.org.uk/guidance/ng882018.">NICE 2018</a>). </p> <p>Heavy menstrual bleeding can be specified more objectively for research reasons by direct or indirect methods for determining menstrual blood loss. The volumetric description of heavy menstrual bleeding is less than 80 mL per cycle and can be assessed using the alkaline hematin method from menstrual sanitary pads and tampons after careful collection or a semi‐quantitative method using pictorial blood loss assessment charts (PBAC; <a href="./references#CD006034-bbs2-0050" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Laboratory Investigation1964;16:244-8.">Hallberg 1964</a>; <a href="./references#CD006034-bbs2-0057" title="HighamJM , O'BrienPM , ShawRW . Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology1990;97:734-9.">Higham 1990</a>; <a href="./references#CD006034-bbs2-0065" title="NewtonJ , BarnardG , CollinsW . A rapid method for measuring menstrual blood loss using automatic extraction. Contraception1977;16(3):269-82.">Newton 1977</a>). </p> </section> <section id="CD006034-sec-0011"> <h3 class="title" id="CD006034-sec-0011">Description of the intervention</h3> <p>Several interventions have been studied for the treatment of heavy menstrual bleeding and pain associated with IUD use, among which are nonsteroidal anti‐inflammatory drugs (NSAIDs), such as mefenamic acid; naproxen; indomethacin; aspirin; and antifibrinolytics, such as tranexamic acid. Other interventions studied include hormones such as desmopressin and estradiol, vitamins, flavonoids, paracetamol, and alternative therapies. </p> </section> <section id="CD006034-sec-0012"> <h3 class="title" id="CD006034-sec-0012">How the intervention might work</h3> <p>Increased fibrinolytic activity and increased prostaglandin release play a role in bleeding and pain associated with Cu IUD use (<a href="./references#CD006034-bbs2-0048" title="GodfreyEM , FolgerSG , JengG , JamiesonDJ , CurtisKM . Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception2013;87(5):549-66.">Godfrey 2013</a>; <a href="./references#CD006034-bbs2-0073" title="YlikorkalaO . Prostaglandin synthesis inhibitors in menorrhagia, intrauterine contraceptive device-induced side effects and endometriosis. Pharmacology and Toxicology1994;75:86-8.">Ylikorkala 1994</a>). Endometrial concentrations of some prostaglandin metabolites correlate with measured blood loss in Cu IUD users (<a href="./references#CD006034-bbs2-0073" title="YlikorkalaO . Prostaglandin synthesis inhibitors in menorrhagia, intrauterine contraceptive device-induced side effects and endometriosis. Pharmacology and Toxicology1994;75:86-8.">Ylikorkala 1994</a>). As for LNG IUD, it has been hypothesized that progesterone causes increased fragility of the superficial vessels of the endometrium as well as endometrial atrophy (<a href="./references#CD006034-bbs2-0052" title="HickeyM , d'ArcanguesC . Vaginal bleeding disturbances and implantable contraceptives. Contraception2002;65(1):75-84.">Hickey 2002</a>). </p> <p>NSAIDs act as inhibitors of prostaglandin synthetase and decrease the release of endometrial prostaglandin, while tranexamic acid exerts its antifibrinolytic effect by inhibiting the endometrial plasminogen activator, preventing fibrinolysis and the breakdown of clots (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>). NSAIDs and fibrinolytic agent such as tranexamic acid have been recommended by the World Health Organization's (WHO) <i>Selected Practice Recommendations for Contraceptive Use</i> as possible treatments for heavy menstrual bleeding among Cu IUD users (<a href="./references#CD006034-bbs2-0072" title="World Health Organization. Medical eligibility criteria for contraceptive use. www.who.int/publications/i/item/9789241549158.">WHO 2015</a>). </p> <p>Flavonoids have been shown to inhibit the release of the inflammatory mediators prostaglandin E2, prostaglandin F2a, thromboxane A2 and prostacyclin and thus reduce capillary hyper‐fragility, increase lymphatic drainage, normalize capillary permeability and strengthen capillary resistance (<a href="./references#CD006034-bbs2-0060" title="Lyseng-WilliamsonKA , PerryCM . Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs2002;63(1):71-100.">Lyseng‐Williamson 2003</a>; <a href="./references#CD006034-bbs2-0061" title="MantheyJA . Biological properties of flavonoids pertaining to inflammation. Microcirculation2000;7(S1):S29-S34.">Manthey 2000</a>). These mechanisms of action are thought to reduce heavy menstrual bleeding and pain associated with Cu and LNG IUD use. </p> </section> <section id="CD006034-sec-0013"> <h3 class="title" id="CD006034-sec-0013">Why it is important to do this review</h3> <p>IUD users give the reasons for discontinuation of IUD use as heavy menstrual bleeding and pain associated with IUDs. The discontinuation of IUD use due to pain was 28% (LNG IUD) to 35% (Cu IUD), while due to heavy bleeding it was 9% (LNG IUD) and 19% (Cu IUD) (<a href="./references#CD006034-bbs2-0026" title="GrunlohDS , CasnerT , SecuraG , PeipertJF , MaddenT . Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstetrics and Gynecology2013;122(6):1214-21. ">Grunloh 2013</a>). This percentage is large and in turn affects many women, given the current use of IUDs worldwide (159 million women; <a href="./references#CD006034-bbs2-0071" title="United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet. www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf.">United Nations 2019</a>). As IUDs are highly effective, safe, cost‐effective and well tolerated by most women, strategies to treat and prevent heavy menstrual bleeding and pain associated with its use should be sought to ensure uptake of this contraceptive method and reduce discontinuation rates. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006034-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006034-sec-0014"></div> <p>To evaluate all randomized controlled trials (RCTs) that have assessed strategies for treatment and prevention of heavy menstrual bleeding or pain associated with IUD use, for example, pharmacotherapy and alternative therapies. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006034-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006034-sec-0015"></div> <section id="CD006034-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006034-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all RCTs in any language that compared any intervention for treating heavy menstrual bleeding or pain associated with any IUD use. We excluded cohort trials and before‐after trials. Interventions for pain during IUD insertion have been examined in another Cochrane Review (<a href="./references#CD006034-bbs2-0059" title="LopezLM , BernholcA , ZengY , AllenRH , BartzD , O'BrienPA , et al. Interventions for pain with intrauterine device insertion. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD007373. [DOI: 10.1002/14651858.CD007373.pub3]">Lopez 2015</a>). The intervention could be compared with no intervention, placebo or another active intervention. We excluded pathological causes of heavy menstrual bleeding and post‐menopausal bleeding. </p> </section> <section id="CD006034-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included women of reproductive age (15 to 49 years) of any gravidity and parity who were using an IUD for contraception. </p> </section> <section id="CD006034-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included any pharmacological or other interventions used either for the treatment or the prevention of heavy menstrual bleeding or pain, or both, associated with IUD use. Comparisons included placebo, no intervention or another active intervention. Types of intervention may include NSAIDs, antifibrinolytics, hormones, other drugs or complementary alternative therapies. </p> </section> <section id="CD006034-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD006034-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>We searched the Core Outcome Measures in Effectiveness Trials (COMET) database (<a href="https://www.comet-initiative.org/" target="_blank">www.comet-initiative.org</a>), to see if a core outcome set had been developed for the outcomes in heavy menstrual bleeding. We found one ongoing trial in the Core Outcomes in Women’s and Newborn health (CROWN) initiative (<a href="http://www.comet-initiative.org/Studies/Details/789" target="_blank">www.comet-initiative.org/Studies/Details/789</a>). Therefore, after discussion between the review authors, we have chosen the primary and secondary outcomes below. </p> <p> <ul id="CD006034-list-0001"> <li> <p>Volume of menstrual blood loss: outcome measures for bleeding included quantitative measurements of blood loss (<a href="./references#CD006034-bbs2-0050" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Laboratory Investigation1964;16:244-8.">Hallberg 1964</a>), semi‐quantitative assessments of blood loss by PBAC scores (<a href="./references#CD006034-bbs2-0057" title="HighamJM , O'BrienPM , ShawRW . Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology1990;97:734-9.">Higham 1990</a>; <a href="./references#CD006034-bbs2-0068" title="ReidPC , CokerA , ColtartR . Assessment of menstrual blood loss using a pictorial chart: a validation study. British Journal of Obstetrics and Gynaecology2000;107:320-2.">Reid 2000</a>), or IUD discontinuation (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>) and number of sanitary pads used for bleeding. Participant perceptions of bleeding being more abundant than usual using categorical scales or menstrual diary cards could also be included. </p> </li> <li> <p>Duration of bleeding: duration of bleeding in number of bleeding or spotting days</p> </li> <li> <p>Painful menstruation: level of pain could be reported on Likert scales, pain scores, qualitatively or any pain reduction </p> </li> </ul> </p> </section> <section id="CD006034-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006034-list-0002"> <li> <p>IUD removal</p> </li> <li> <p>Haemoglobin levels</p> </li> <li> <p>Need for additional analgesia</p> </li> <li> <p>Quality of life measured by any validated scales</p> </li> <li> <p>Side effects and adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD006034-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane Fertility Regulation Information Specialist conducted a search for all published, unpublished, and ongoing trials, without restrictions on language or publication status till 28 January 2021. The search strategies for each database were modelled on the search strategy designed for MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations and Daily), available in <a href="./appendices#CD006034-sec-0122">Appendix 1</a>. </p> <section id="CD006034-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from their inception.</p> <p> <ul id="CD006034-list-0003"> <li> <p>EBM Reviews Ovid (1974 to 28 January 2021)</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 12)</p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations and Daily) (1946 to 28 January 2021) </p> </li> <li> <p>Embase.com (1974 to 28 January 2021)</p> </li> <li> <p>CINAHL (1982 to 28 January 2021)</p> </li> <li> <p>LILACs <a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en/</a> (1982 to 28 January 2021) </p> </li> <li> <p>Global Health Ovid (inception to 28 January 2021)</p> </li> <li> <p>Scopus (inception to 28 January 2021)</p> </li> </ul> </p> <p>We searched the following trials registries:</p> <p> <ul id="CD006034-list-0004"> <li> <p>The World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) (up to 28 January 2021) </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (up to 28 January 2021) </p> </li> </ul> </p> <p>We searched the following grey literature sites:</p> <p> <ul id="CD006034-list-0005"> <li> <p>Guttmacher Institute (<a href="https://www.guttmacher.org/united-states/abortion" target="_blank">www.guttmacher.org/united-states/abortion</a>) (up to 28 January 2021) </p> </li> <li> <p>International Planned Parenthood Federation (<a href="https://www.ippf.org/" target="_blank">www.ippf.org/</a>) (up to 28 January 2021) </p> </li> <li> <p>Ibis Reproductive Health (<a href="https://ibisreproductivehealth.org/" target="_blank">ibisreproductivehealth.org/</a>) (up to 28 January 2021) </p> </li> <li> <p>Women on Waves (<a href="https://www.womenonwaves.org/" target="_blank">www.womenonwaves.org/</a>) (up to 28 January 2021) </p> </li> <li> <p>Marie Stopes International (<a href="https://www.mariestopes.org/" target="_blank">www.mariestopes.org/</a>) (up to 28 January 2021) </p> </li> <li> <p>Population Council (<a href="https://www.popcouncil.org/" target="_blank">www.popcouncil.org/</a>) (up to 28 January 2021) </p> </li> <li> <p>Population Services International (<a href="https://www.psi.org/" target="_blank">www.psi.org/</a>) (up to 28 January 2021) </p> </li> <li> <p>Ipas (<a href="https://www.ipas.org/" target="_blank">www.ipas.org/</a>) (up to 28 January 2021) </p> </li> </ul> </p> </section> <section id="CD006034-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and any relevant systematic reviews identified for further references to relevant trials. We contacted experts and organizations in the field to obtain additional information on relevant trials. We wrote to authors of published trial reports to solicit other published or unpublished trials that we may have missed. We also contacted trial report authors as needed to supplement published information. </p> </section> </section> <section id="CD006034-sec-0026"> <h3 class="title" id="CD006034-sec-0026">Data collection and analysis</h3> <p>For this update, we applied the techniques below to evaluate the reports that we discovered as a result of the updated search, and we went back over the trial reports in the 2011 publication to assign them to the proper comparison and to revise their risk of bias. </p> <section id="CD006034-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed and abstracted data from the trials identified to improve accuracy. We resolved any discrepancies or disagreements through discussion or by involving a third review author if needed. </p> </section> <section id="CD006034-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted the data for the eligible trials. We solved inconsistencies through discussion or, if necessary, we sought advice from the third review author. We entered data into Review Manager 5 software (<a href="./references#CD006034-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), and checked accuracy. When any information was doubtful, we tried to contact authors of the original reports for further details. </p> </section> <section id="CD006034-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each trial using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006034-bbs2-0054" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We resolved any disagreement by discussion, or by involving a third review author. The biases related to this review were: selection bias (random sequence generation; allocation concealment); performance bias (blinding of participants and personnel); detection bias (blinding of outcome assessors); attrition bias (incomplete outcome data); reporting bias (selective reporting); and other forms of bias (such as baseline imbalance, selective reporting of subgroups, or potential influence from funders). Conclusions were assigned to each of these domains (<a href="./references#CD006034-bbs2-0054" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We graded each risk of bias domain as 'low', 'unclear' or 'high', We described all judgements fully and presented the conclusions in the <a href="#CD006034-sec-0063">Risk of bias in included studies</a>. We assessed the likely magnitude and direction of the bias and whether it was likely to impact the findings. We explored impact of bias by performing sensitivity analysis. We also noted funding source for trials and declaration of interest by trial authors. </p> </section> <section id="CD006034-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous variables, we computed the mean difference (MD) with 95% confidence interval (CI). We used standardized mean difference (SMD) if trials in the meta‐analysis used different measurement scales. We would interpret SMD as 0.2 small effect, 0.5 moderate effect and 0.8 a large effect (<a href="./references#CD006034-bbs2-0042" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.">Cohen 1988</a>). For dichotomous outcomes, we calculated odds ratio (OR) with 95% CI. We used a random‐effects model in meta‐analysis. We presented data as provided by the trial authors, for trials that reported in medians, ranges and percentages. </p> </section> <section id="CD006034-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We checked included trials for unit of analysis errors, and we did not encounter any of these. If we had encountered any cluster‐RCTs we intended to adjust the results from trials showing unit of analysis errors based on the mean cluster size and intra‐cluster correlation coefficient (<a href="./references#CD006034-bbs2-0055" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021a</a>). </p> </section> <section id="CD006034-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For included trials, we noted levels of attrition. We had proposed to investigate the influence of including trials with high levels of missing data in the whole assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we conducted analyses, as far as feasible, on an intention‐to‐treat basis. </p> </section> <section id="CD006034-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We deemed whether the clinical and methodological qualities of the included trials were adequately similar for meta‐analysis to provide a meaningful summary. Where we were able to carry out meta‐analyses, we checked for heterogeneity by visually inspecting the forest plots for evidence of poor overlap of the 95% CIs. More accurately, we used the Chi<sup>2</sup> test (with a P value less than 0.10 being evidence of significance) and the I<sup>2</sup> statistic value (<a href="./references#CD006034-bbs2-0053" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006034-bbs2-0044" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>), suggested a rough guide for interpretation of I<sup>2</sup> statistic values: </p> <p> <ul id="CD006034-list-0006"> <li> <p>0% to 40% might not be important;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100% was considerable heterogeneity.</p> </li> </ul> </p> <p>Where we found substantial heterogeneity (I<sup>2</sup> statistic &gt; 50%), we aimed to look at possible sources involving variations in trial quality, inclusion criteria or intervention regimes among trials. </p> </section> <section id="CD006034-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to minimize the likelihood of reporting bias by conducting a comprehensive search for eligible trials with no restriction to language or publication status and by being alert to duplication of data. Despite these efforts, it is still possible that we may have missed some trials, so our conclusions should be interpreted with some caution. If we found 10 or more trials for the primary outcomes, we planned to use a funnel plot to explore the possibility of small‐trial effects. </p> </section> <section id="CD006034-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software (<a href="./references#CD006034-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We applied a random‐effects model in meta‐analysis for merging data as we believed it was acceptable to presume that there was clinical heterogeneity due to the huge difference in the type of intervention used (<a href="./references#CD006034-bbs2-0044" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>). There was also variation in the subjective assessment of volume of menstrual blood loss and level of pain. These variations directed us to believe that the underlying treatment effects would differ between trials. Cross‐over trials are a suitable design to evaluate stable, chronic conditions (<a href="./references#CD006034-bbs2-0056" title="HigginsJP , EldridgeS , Li T editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>). We therefore anticipated trials with cross‐over design in this review, as bleeding or pain associated with IUD use is a recurrent condition. However, to date, the reporting of cross‐over trials is variable, and the data needed to include a paired analysis in a meta‐analysis is often unpublished. We made an a priori decision to include only data from the first period if available and to report the rest of the cross‐over data in the review. </p> </section> <section id="CD006034-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we planned to undertake subgroup analyses according to type and dose of interventions. However, there were insufficient trials to undertake subgroup analyses. </p> </section> <section id="CD006034-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Akin to the previous review, we did not perform sensitivity analyses due to the inability to aggregate the included trials. We intended to do sensitivity analysis when there was high risk of bias for sequence generation and allocation concealment of included trials. Future updates may undertake this analysis if there are an adequate number of relevant trials. </p> </section> <section id="CD006034-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD006034-sec-0039"> <h5 class="title">Assessing the certainty of evidence using the GRADE approach</h5> <p>We used the GRADE approach to assess the certainty of the body of evidence for this update, relating to the following outcomes for the main comparisons. </p> <p> <ul id="CD006034-list-0007"> <li> <p>Menstrual blood loss</p> </li> <li> <p>Duration of bleeding</p> </li> <li> <p>Level of pain</p> </li> </ul> </p> <p>We used the GRADEPro GDT development tool (<a href="./references#CD006034-bbs2-0049" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 14 November 2021. Available at gradepro.org.">GRADEpro GDT</a>), to import data from Review Manager 5 (<a href="./references#CD006034-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), to create the summary of findings tables. Using the GRADE approach, we generated a summary of the intervention effect and measure of certainty for each of the above outcomes. </p> <p>The GRADE approach uses five considerations (trial limitations, consistency of effect, indirectness, imprecision and publication bias) to assess the certainty of the body of evidence for each outcome. We downgraded the evidence from 'high certainty' by one level for serious (or by two levels for very serious) weaknesses, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006034-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006034-sec-0040"></div> <section id="CD006034-sec-0041"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>; <a href="./references#CD006034-sec-0136" title="">Characteristics of excluded studies</a>; <a href="./references#CD006034-sec-0137" title="">Characteristics of studies awaiting classification</a>; Characteristics of ongoing studies; <a href="#CD006034-tbl-0009">Table 1</a>; <a href="#CD006034-tbl-0010">Table 2</a>. </p> <div class="table" id="CD006034-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of treatment trials interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Experimental Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>IUD type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Effectiveness trials</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 1250 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 500 mg on 1st day then 750 mg on subsequent days</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 cycles</p> <p>Each participant took 2 of the 3 treatments, each for 2 menstrual cycles.</p> <p>Each regimen was begun on the 1st day of menstrual bleeding and continued for a total of 5 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After every 2 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage reduction in menstrual blood loss</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ulipristal acetate 5 mg/day for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 days, bleeding was assessed at 30 days, 60 days and 70 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bleeding days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral vitamin B1 100 mg/day during the 2nd, 3rd and 4th months following insertion of the IUD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo</p> <p>during the 2nd, 3rd and 4th months following insertion of the IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after completion of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of pads used</p> <p>Number of spotting days</p> <p>Duration of bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Pain trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen sodium 550 mg initially, then 275 mg every 6 hours as needed for uterine pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (lactose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown IUD type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall and daily pain relief score (6‐point Likert scale)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 500 mg followed by 250 mg 2‐4 times a day, with a maximum of 1250 mg, taken at the first sign of menstrual distress. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo taken at the first sign of menstrual distress.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 cycles</p> <p>Participant took an intervention for 2 cycles then crossed over to the other intervention for 2 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 2nd and 4th menstrual cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain relief (5‐point Likert scale)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b><i>Comparative effectiveness trials</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Bleeding trials</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 500 mg, 1 tablet 6‐hourly during the 1st 3 days of menstrual bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral micronized flavonoid 500 mg, 1 tablet 6‐hourly during the 1st 3 days of menstrual bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> <p>Number of pads used/day</p> <p>Number of bleeding days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid, 250 mg; 1 capsule every 8 hours on the first 3 days of menstruation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid, 250 mg; 1 capsule every 8 hours on the first 3 days of menstruation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> <p>Number of bleeding days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desmopressin 300 mcg intranasal spray each morning for the first 5 days after start of menstruation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 1500 mg/day for the first 5 days after the start of menstruation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 500 mg 3 times/day for 3‐5 days based on the duration of bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 500 mg 3 times/day for 3‐5 days based on the duration of bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volume of blood loss</p> <p>Duration of bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 250 mg 3 times/day from the 1st day of menstruation until day 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral Vitex agnus 3 times/day from the 1st day of menstruation until day 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown IUD type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 4.5 g/day for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral sodium diclofenac 150 mg on day 1 then 75 mg/day on days 2‐4</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 months</p> <p>Each participant received placebo for 1 month, 2 months of tranexamic acid, and 2 months of sodium diclofenac </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> <p>Duration of bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cu IUD:</b> copper intrauterine device; <b>HMB:</b> heavy menstrual bleeding; <b>IUD:</b> intrauterine device; <b>LNG IUD:</b> levonorgestrel intrauterine device; <b>PBAC:</b> pictorial blood loss assessment chart </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006034-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of prevention trials interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Experimental intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>IUD type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Effectiveness trials</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ibuprofen 1200 mg/day at the beginning of menstruation and to continue to end of bleeding for a maximum of 10 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo at the beginning of menstruation and to continue to end of bleeding for a maximum of 10 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> <p>Length of menstruation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ibuprofen 1600 mg/day starting with bleeding and continuing until end of bleeding or maximum of 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo starting with bleeding and continuing until end of bleeding or maximum of 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> <p>Cu Lippes loop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> <p>Each participant had 1 month of observation, 1 month on ibuprofen or placebo, and 1 month crossed over to the alternative treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of month 1, 2, 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral CDB‐2914 50 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention taken for 3 consecutive days with separate treatments starting 21, 49 and 77 days after LNG IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1,3 and 6 months after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage days bleeding/ spotting, removal of LNG IUD within 6 months; the longest run of amenorrhoea in the 64 days after third treatment, side effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding and pain trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ibuprofen 1200 mg/day to be taken with the first 6 menstruations after IUD insertion and for a maximum of 5 days at a time. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo to be taken with the first 6 menstruations after IUD insertion and for a maximum of 5 days at a time. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 13, 26 and 52 weeks after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IUD removal within 12 months of insertion due to HMB/pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tolfenamic acid 600 mg/day starting at IUD insertion and continuing for 7 days; this was to be repeated during the next 3 menstruations. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo starting at IUD insertion and continuing for 7 days; this was to be repeated during the next 3 menstruations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of pads used,</p> <p>menstruation more abundant than normal, clots,</p> <p>menstruation more painful than normal</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Comparative effectiveness trials</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral aspirin 1500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral paracetamol 1500 mg/day</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> <p>Interventions taken on day 1 of menstruation and continued for the duration of bleeding.</p> <p>Each participant received each treatment in alternating order.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 2 g/day, taken for the 1st 5 days of 3 consecutive cycles after IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 1 g/day, taken for the 1st 5 days of 3 consecutive cycles after IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage occurrence of HMB by alkaline hematin and PBAC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 500 mg twice a day first 5 days of a 4‐week period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transdermal estradiol 0.1 mg on day after insertion of IUD, changing it weekly</p> <p>Oral placebo twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First 12 weeks of IUD use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone surveys at 4, 8, and 16 weeks and an in‐person follow‐up visit at 12</p> <p>weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median bleed days, patient satisfaction, continuation rates of IUD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral 50 mg mifepristone every other day starting on the 1st day of the menstrual cycle for the pre‐treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral vitamin B every other day starting on the 1st day of the menstrual cycle for the pre‐treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months (corresponding to 2 menstrual cycles i.e. 2 × 28 days) prior to insertion and until 3 days (± 2 days) following the LNG IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for the first 3 months, 6 months post‐LNG IUD</p> <p>insertion and 12 months end‐of‐trial</p> <p>evaluation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding and spotting days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 1500 mg/day, taken on the 1st day of a bleeding or spotting episode until bleeding or spotting stopped </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 1500 mg/day, taken on the 1st day of a bleeding or spotting episode until bleeding or spotting stopped </p> <p>Oral placebo (lactose and magnesium stearate), taken on the 1st day of a bleeding or spotting episode until bleeding or spotting stopped </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median reduction of bleed days and length of bleed days, satisfaction with drug/placebo, occurrence of pain, number of days pain medication used to alleviate pain, adverse effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cu IUD:</b> copper intrauterine device; <b>HMB:</b> heavy menstrual bleeding; <b>IUD:</b> intrauterine device; <b>LNG IUD:</b> levonorgestrel intrauterine device; <b>PBAC:</b> pictorial blood loss assessment chart </p> </td> </tr> </tbody> </table> </div> <section id="CD006034-sec-0042"> <h4 class="title">Results of the search</h4> <p>For this update, we retrieved 591 records from the search conducted in January 2021.</p> <p>We also re‐examined trials from the previous version of the review (<a href="./references#CD006034-bbs2-0074" title="GrimesDA , HubacherD , LopezLM , SchulzKF . Non‐steroidal anti‐inflammatory drugs for heavy bleeding or pain associated with intrauterine‐device use. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006034. [DOI: 10.1002/14651858.CD006034.pub2]">Grimes 2006</a>): there were 15 included trials, 10 excluded trials, and two ongoing trials. </p> <p>We excluded 11 trials (<a href="#CD006034-fig-0001">Figure 1</a>). Eight trials were awaiting classification due to inability to retrieve full texts; six from the previous review (<a href="./references#CD006034-bbs2-0034" title="Di LietoA , CatalanoD , MirandaL , PaladiniA . Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding. Clinical and Experimental Obstetrics and Gynecology1987;14:41-4. ">Di Lieto 1987</a>; <a href="./references#CD006034-bbs2-0035" title="JensenHH , BlaabjergJ , LyndrupJ . Prophylactic use of prostaglandin synthetase inhibitors in connection with IUD insertion [Profylaktisk brug af prostaglandinsyntesehaemmere ved oplaegning af spiral]. Ugeskrift for Laeger1998;160:6958-61. ">Jensen 1998</a>; <a href="./references#CD006034-bbs2-0036" title="MasseySE , VaradyJC , HenzlMR . Pain relief with naproxen following insertion of an intrauterine device. Journal of Reproductive Medicine1974;13:226-31. ">Massey 1974</a>; <a href="./references#CD006034-bbs2-0037" title="ToppozadaM , AnwarM , Abdel RahmanH , GaweeshS . Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs. Contraceptive Delivery Systems1982;3:117-25. ">Toppozada 1982</a>; <a href="./references#CD006034-bbs2-0039" title="WuS , WangC , ChengW , HanX , WangS , QiJ . Randomized multi-center study of baofuxin for treatment of bleeding side-effect induced by IUD. Reproduction and Contraception2000;11:152-7. ">Wu 2000</a>; <a href="./references#CD006034-bbs2-0040" title="YarkoniS , AntebySO . Treatment of IUD related menorrhagia by indomethacin. Clinical and Experimental Obstetrics and Gynecology1984;11:120-2. ">Yarkoni 1984</a>), and two from our new search (<a href="./references#CD006034-bbs2-0033" title="Bayer Healthcare AG. International, prospective, double-blind, 3-arm comparative, randomized, placebo-controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on the management of bleeding/spotting in women using the levonorgestrel-releasing intrauterine system (MIRENA) for contraception. clinicaltrials.bayer.com/study/?id=15105. ">Bayer 2013</a>; <a href="./references#CD006034-bbs2-0038" title="WangLY , LiSZ , WuSY , ZhaoYH , WangY . A random control study of indomethacin-containing MYCu intrauterine contraceptive device for 60 months. Zhonghua Yi Xue Za Zhi2013;93(7):496-9. ">Wang 2013</a>). There were no ongoing trials. </p> <div class="figure" id="CD006034-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram" data-id="CD006034-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram</p> </div> </div> </div> </section> <section id="CD006034-sec-0043"> <h4 class="title">Included studies</h4> <p>This update includes 21 trials with a total of 3689 participants. Of those, 11 trials were included in the previous review (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). One trial was excluded from the previous review (<a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>), and we included nine new trials from the updated search (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). See <a href="#CD006034-fig-0001">Figure 1</a> for the PRISMA flow diagram (<a href="./references#CD006034-bbs2-0067" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmanTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71.">Page 2021</a>). </p> <p>Of the 20 included trials, five trials with a total of 104 participants were randomized controlled trials (RCTs) with cross‐over design (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). The number of participants in each trial ranged from 19 to 2019. The 20 trials were undertaken in 10 countries. Four trials were conducted in Iran (<a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>), three in the USA (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>), three in Sweden (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>), three in Finland (<a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>), two in the UK (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>), one in Egypt (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>), one in Chile (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>), one in China (<a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>), one in Brazil (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>) and one in Italy (<a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>). One trial (<a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>), involved three countries, which were Denmark, Ireland and Norway. Six trials were multi‐centre trials (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>). </p> <p>Participants’ age ranged from 15 to 49 years old. Cu IUD was used by participants in 12 trials (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>), Cu IUD and Lippes Loop in one trial (<a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>), and LNG IUD in five trials (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). Three trials did not state the type of IUD used (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). See <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>. </p> </section> <section id="CD006034-sec-0044"> <h4 class="title">Treatment trials</h4> <p>Seven trials were among Cu IUD users. There were two effectiveness trials (<a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>), and five comparative effectiveness trials (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). Five trials focused on the treatment of heavy menstrual bleeding associated with IUD use (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>), one trial on the treatment of pain associated with IUD use (<a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>), and one trial on treatment of pain and bleeding associated with IUD use (<a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). </p> <p>LNG IUD was used in one treatment of bleeding effectiveness trial (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>). Details are in <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>. </p> <p>The IUD type was uncertain in two treatment of bleeding effectiveness trials (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>), and one treatment of pain comparative effectiveness trial (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>). </p> <p><a href="#CD006034-tbl-0009">Table 1</a> summarizes the experimental and comparison interventions for the treatment trials. Additional details are given in <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>. </p> <p>The following are the interventions for the treatment of bleeding and pain.</p> <p>Cu IUD</p> <p> <ul id="CD006034-list-0008"> <li> <p>Treatment of heavy menstrual bleeding</p> <ul id="CD006034-list-0009"> <li> <p>Vitamin B1 versus placebo</p> </li> <li> <p>Naproxen versus placebo</p> </li> <li> <p>Mefenamic acid versus tranexamic acid</p> </li> <li> <p>Mefenamic acid versus desmopressin</p> </li> <li> <p>Tranexamic acid versus diclofenac</p> </li> <li> <p>Tranexamic acid versus flavonoids</p> </li> <li> <p>Tranexamic acid versus active comparators (mefenamic acid, flavonoids, diclofenac)</p> </li> </ul> </li> <li> <p>Treatment of pain</p> <ul id="CD006034-list-0010"> <li> <p>Tranexamic acid versus diclofenac</p> </li> </ul> </li> </ul> </p> <p>LNG IUD</p> <p> <ul id="CD006034-list-0011"> <li> <p>Treatment of heavy menstrual bleeding</p> <ul id="CD006034-list-0012"> <li> <p>Ulipristal versus placebo</p> </li> </ul> </li> <li> <p>Treatment of pain ‐ none</p> </li> </ul> </p> <p>Unknown IUD type</p> <p> <ul id="CD006034-list-0013"> <li> <p>Treatment of heavy menstrual bleeding</p> <ul id="CD006034-list-0014"> <li> <p>Higher dose versus lower dose naproxen</p> </li> <li> <p>Mefenamic acid versus Vitex agnus</p> </li> </ul> </li> <li> <p>Treatment of pain</p> <ul id="CD006034-list-0015"> <li> <p>Naproxen versus placebo</p> </li> </ul> </li> </ul> </p> <section id="CD006034-sec-0045"> <h5 class="title">Treatment of heavy bleeding associated with IUD use</h5> <section id="CD006034-sec-0046"> <h6 class="title">Cu IUD</h6> <p>The five treatment of bleeding trials included a total of 544 Cu IUD users, with sample size ranging from 24 to 210 women. The age of the women ranged from 18 to 49 years old. </p> <p>One trial studied oral vitamin B1 compared to placebo (dried starch; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>). The dose of vitamin B was 100 mg per day taken during the second through fourth month of menstruation. </p> <p>Three trials studied NSAIDs (<a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>). Two trials compared mefenamic acid to tranexamic acid (<a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>). The dose of mefenamic acid used was 750 mg per day in comparison tranexamic acid 750 mg per day for the first three days of menstruation for a total of two menstrual cycles (<a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>), while the other trial used 1500 mg mefenamic acid compared to 1500 mg tranexamic acid for three to five days, depending on the duration of bleeding, for three cycles (<a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>). An Italian RCT compared oral mefenamic acid 1500 mg per day to intranasal desmopressin 300 mcg per day for the first five days of menstruation for a duration of three cycles (<a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>). </p> <p>One trial studied oral tranexamic acid at a dose of 2 g per day compared to oral flavonoids at a dose of 2 g per day, taken on the first three days of menstruation for duration of three cycles (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>). </p> <p>Five trials assessed menstrual blood loss by applying PBAC (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>). One trial (<a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>), evaluated menstrual blood loss using a different pictorial chart, where each pad was perceived as lightly (10 mL), mildly (20 mL), moderately (30 mL), or completely saturated (40 mL). </p> </section> <section id="CD006034-sec-0047"> <h6 class="title">LNG IUD</h6> <p>One trial among 30 LNG IUD users compared 5 mg oral ulipristal acetate per day, taken for five days, to oral placebo (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>). Duration of bleeding was reported as the number of days until bleeding stopped as well as the number of bleeding days in 90 days. </p> </section> <section id="CD006034-sec-0048"> <h6 class="title">Unknown IUD type</h6> <p>One trial compared naproxen sodium at 1250 mg to 500 mg on the first day then 750 mg on subsequent days or placebo on day one to five of menstruation, for a total of two menstrual cycles per intervention (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>). No method of blood loss quantification was reported. </p> <p>Another trial compared oral mefenamic acid 750 mg per day to oral Vitex agnus 750 mg per day for the first eight days of menstruation for a duration of four months (<a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). Blood loss was assessed using a PBAC. </p> </section> </section> <section id="CD006034-sec-0049"> <h5 class="title">Treatment of pain associated with IUD use</h5> <section id="CD006034-sec-0050"> <h6 class="title">Cu IUD</h6> <p>One trial involving 21 Cu IUD users examined the use of naproxen sodium against placebo for the treatment of pain (<a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>). This trial was a cross‐over design that compared oral naproxen at a dose of 500 mg initially followed by 250 mg two to four times per day as needed for two cycles followed by placebo for two cycles or vice versa. Pain was assessed using a Likert scale with scale of five being excellent relief and scale of one being worst pain. </p> </section> <section id="CD006034-sec-0051"> <h6 class="title">Unknown IUD type</h6> <p>One trial with an unknown IUD type randomized 35 women to receive either naproxen sodium (550 mg initially, then 275 mg every six hours as needed) versus a placebo (lactose) for three consecutive menstrual cycles (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>). Pain was assessed by a self‐administered six‐point Likert scale with 6 being excellent relief and 1 being no relief. </p> </section> </section> <section id="CD006034-sec-0052"> <h5 class="title">Treatment of bleeding and pain associated with IUD use</h5> <section id="CD006034-sec-0053"> <h6 class="title">Cu IUD</h6> <p>One trial assessed treatment of heavy menstrual bleeding and pain associated with IUD use (<a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). The trial consisted of 19 women on Cu IUD, studied during five cycles. In randomized order, they received for two cycles oral tranexamic acid, 1.5 g three times daily for five days; in another two cycles they received sodium diclofenac, 50 mg three times daily on the first day followed by 25 mg three times daily for four days and placebo for five days in another cycle. <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a> assessed menstrual blood loss using the alkaline hematin method, but did not describe the method for pain assessment. </p> </section> </section> </section> <section id="CD006034-sec-0054"> <h4 class="title">Prevention trials</h4> <p>There were 10 prevention trials (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). Six were effectiveness trials, while four were comparative effectiveness, as detailed below (see <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a> and <a href="#CD006034-tbl-0010">Table 2</a>). </p> <p>Four trials in women with Cu IUD were effectiveness trials (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>), while two were comparative effectiveness trial (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>). Three trials examined prevention of heavy menstrual bleeding associated with Cu IUD (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>), while another three trials looked at the prevention of both bleeding and pain (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). </p> <p>Four trials assessed the prevention of bleeding associated with LNG IUD use (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). Only one was an effectiveness trial (<a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). </p> <p><a href="#CD006034-tbl-0010">Table 2</a> summarizes the experimental and comparison interventions for the 10 prevention trials. Additional details are given in <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>. </p> <p>Prevention of pain ‐ There were 11 treatment trials. Five were effectiveness trials, while six were comparative effectiveness, as detailed below (see <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>; <a href="#CD006034-tbl-0009">Table 1</a>) </p> <p>The following are the interventions for the prevention of bleeding and pain:</p> <p>Cu IUD</p> <p> <ul id="CD006034-list-0016"> <li> <p>Prevention of heavy menstrual bleeding</p> <ul id="CD006034-list-0017"> <li> <p>Ibuprofen versus placebo</p> </li> <li> <p>Tolfenamic acid versus placebo</p> </li> <li> <p>Aspirin versus paracetamol</p> </li> <li> <p>2 g tranexamic acid versus 1 g tranexamic acid</p> </li> </ul> </li> <li> <p>Prevention of pain</p> <ul id="CD006034-list-0018"> <li> <p>Ibuprofen versus placebo</p> </li> <li> <p>Tolfenamic acid versus placebo</p> </li> </ul> </li> </ul> </p> <p>LNG IUD</p> <p> <ul id="CD006034-list-0019"> <li> <p>Prevention of heavy menstrual bleeding</p> <ul id="CD006034-list-0020"> <li> <p>CDB‐2914 (ulipristal) versus placebo</p> </li> <li> <p>Tranexamic acid versus mefenamic acid</p> </li> <li> <p>Mifepristone versus vitamin B1</p> </li> <li> <p>Naproxen versus estradiol</p> </li> </ul> </li> <li> <p>Prevention of pain ‐ none</p> </li> </ul> </p> <section id="CD006034-sec-0055"> <h5 class="title">Prevention of heavy menstrual bleeding associated with IUD use</h5> <section id="CD006034-sec-0056"> <h6 class="title">Cu IUD</h6> <p>One trial examined oral ibuprofen (1200 mg per day) against placebo for three cycles (<a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>), while another trial compared different doses of oral tranexamic acid (2 g per day versus 1 g per day; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>). </p> <p>One trial compared aspirin to paracetamol for the prevention of heavy bleeding (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>). Aspirin, 1500 mg per day was compared to 1500 mg paracetamol taken from day one of menstruation and continued for the duration of bleeding for a total of three menstrual cycles. </p> <p>Two trials assessed menstrual blood loss using the alkaline hematin method (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>), while another trial utilized a PBAC and the alkaline hematin method (<a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>). </p> </section> <section id="CD006034-sec-0057"> <h6 class="title">LNG IUD</h6> <p>Two trials examined NSAIDs for the prevention of bleeding associated with LNG IUD (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>). One trial compared the use of oral mifepristone, 50 mg every other day, to vitamin B, starting on the first day of the menstrual cycle for the pre‐treatment period until three days (± 2 days) following the LNG IUD insertion (<a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>). One trial compared a selective progesterone receptor modulator, Ulipristal acetate to placebo (<a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). Women were randomized to receive oral ulipristal acetate 50 mg per day or placebo, taken for three consecutive days, with separate treatments starting 21, 49 and 77 days after IUD insertion. </p> <p>One trial compared oral naproxen 1 g per day for the first five days to transdermal estradiol 0.1 mg weekly or oral placebo (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>), while the other trial utilized oral tranexamic acid 1500 mg per day against oral mefenamic acid 1500 mg per day and placebo (<a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>). The duration of the intervention in both trials was for three menstrual cycles. </p> <p>Four trials used diaries to record bleeding days and pattern (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). </p> </section> </section> <section id="CD006034-sec-0058"> <h5 class="title">Prevention of bleeding and pain associated with IUD use</h5> <section id="CD006034-sec-0059"> <h6 class="title">Cu IUD</h6> <p>Three trials, with a total of 2199 participants, evaluated prevention of bleeding and pain associated with Cu IUD use (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). Two trials compared ibuprofen to placebo; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a> utilized oral ibuprofen at a dose of 1200 mg per day and <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a> at a dose of 1600 mg per day. One prevention trial compared oral tolfenamic acid 600 mg to placebo (<a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). </p> <p>One trial assessed menstrual blood loss using the alkaline hematin method (<a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>). Subjective assessment of pain in diaries (<a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>) and bleeding pattern records (<a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>) were reported. </p> </section> </section> </section> <section id="CD006034-sec-0060"> <h4 class="title">Sources of trial funding</h4> <p>Fifteen trials reported their sources of funding (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). Four trials received funding from universities (<a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>), four trials were funded by pharmaceutical companies (<a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>), three from government research funding bodies (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>), and one from a charitable private trust (<a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). Two trials received funding from both a pharmaceutical company and government research funding body (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>), and one trial partially from a grant and research council (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>). Six trials did not report their funding (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>). </p> </section> <section id="CD006034-sec-0061"> <h4 class="title">Declaration of interests</h4> <p>Seven trials reported their declaration of interests as ‘none’ (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). One trial (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>), reported a conflict of interest for being a member of a foundation and receiving honorarium by a pharmaceutical company as a speaker. Thirteen trials did not report on declarations of interest by researchers (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). See <a href="./references#CD006034-sec-0135" title="">Characteristics of included studies</a>. </p> </section> <section id="CD006034-sec-0062"> <h4 class="title">Excluded studies</h4> <p>In this update, we excluded 11 trials for several reasons, including seven trials which were non‐randomized controlled trials (<a href="./references#CD006034-bbs2-0024" title="BatárI , ThomasM , LampéL , KesselE . Two modifications of the intrauterine membrane contraceptive device. Fertility and Sterility1978;30(1):54-8. ">Batar 1978</a>; <a href="./references#CD006034-bbs2-0025" title="DreherE , vonFischerB . Treatment of primary dysmenorrhea and dysmenorrhea because of IUD with PG-synthetase inhibitors. Advances in Prostaglandin and Thromboxane Research1980;8:1487-93. ">Dreher 1980</a>; <a href="./references#CD006034-bbs2-0026" title="GrunlohDS , CasnerT , SecuraG , PeipertJF , MaddenT . Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstetrics and Gynecology2013;122(6):1214-21. ">Grunloh 2013</a>; <a href="./references#CD006034-bbs2-0027" title="GuillebaudJ , AndersonAB , TurnbullAC . Reduction by mefenamic acid of increased menstrual blood loss associated with intrauterine contraception. British Journal of Obstetrics and Gynaecology1978;85:53-62. ">Guillebaud 1978</a>; <a href="./references#CD006034-bbs2-0028" title="HidalgoM , BahamondesL , PerrottiM , DiazJ , Dantas-MonteiroC , PettaC . Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception2002;65(2):129-32. ">Hidalgo 2002</a>; <a href="./references#CD006034-bbs2-0029" title="LalS , KriplaniA , KulshresthaV , SharmaM , AgarwalN . Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. International Journal of Obstetrics &amp; Gynaecology2010;109(2):128-30. ">Lal 2010</a>; <a href="./references#CD006034-bbs2-0031" title="ToppozadaM . Treatment of increased menstrual blood loss in IUD users. Contraception1987;36(1):145-57. ">Toppozoda 1987</a>). We excluded four trials as they did not meet the inclusion criteria. <a href="./references#CD006034-bbs2-0022" title="AbbasAM , AbdelkaderAM , ElsayedAH , FahmyMS . The effect of slow versus fast application of vulsellum on pain perception during copper intrauterine device insertion: a randomized controlled trial. Middle East Fertility Society Journal2018;23:143-7. ">Abbas 2018</a>, <a href="./references#CD006034-bbs2-0023" title="BaldwinMK , EdelmanAB , LimJY , NicholsMD , Bednarek, PH, JensenJT . Intrauterine device placement at 3 versus 6 weeks postpartum: a randomized trial. Contraception2016;93:356-63. ">Baldwin 2016</a>, and <a href="./references#CD006034-bbs2-0030" title="TavakolianS , DoulabiMA , BaghbanAA , MortazaviA , GhorbaniM . Lidocaine-prilocaine cream as analgesia for IUD Insertion: a prospective, randomized, controlled, triple blinded study. Global Journal of Health Science2015;7:399-404. ">Tavakolian 2015</a> reported pain perception during IUD insertion, while <a href="./references#CD006034-bbs2-0032" title="Van der HeijdenP , GeominiP , HermanMC , VeersemaS , BongersMY . Timing for insertion of levonorgestrel releasing intrauterine system: a randomized controlled trial. International Journal of Obstetrics &amp; Gynaecology2017;124(2):299-305. ">Van der Heijden 2017</a> did not fulfil the inclusion criteria for type of intervention. See <a href="./references#CD006034-sec-0136" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD006034-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>Summaries of assessments of bias in included studies are shown in <a href="#CD006034-fig-0002">Figure 2</a> and <a href="#CD006034-fig-0003">Figure 3</a>. Details of the appraisals made on risk of bias are described below. </p> <div class="figure" id="CD006034-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials" data-id="CD006034-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials </p> </div> </div> </div> <div class="figure" id="CD006034-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial" data-id="CD006034-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial </p> </div> </div> </div> <section id="CD006034-sec-0064"> <h4 class="title">Allocation</h4> <p>Twelve trials described the method they used to generate the randomization sequence, thus meeting the criteria for low risk of bias (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). Randomization was mostly undertaken by a computer‐generated list of random numbers. For allocation concealment, we found 10 trials to have low risk of bias (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). Eight out of 21 trials met the criteria for low risk of selection bias (both random sequence generation and allocation concealment; <a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). Nine trials had unclear random sequence generation (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>), while 11 trials had unclear allocation concealment (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). There were no trials with high risk of selection bias. </p> </section> <section id="CD006034-sec-0065"> <h4 class="title">Blinding</h4> <section id="CD006034-sec-0066"> <h5 class="title">Performance bias</h5> <p>Ten trials met the criteria for low risk of performance bias that ensured blinding of participants and investigators because the control groups had treatment regimens identical in appearance to the experimental intervention (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). We found two trials to have high risk of performance bias because the route of administration of the experimental intervention was transdermal (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>), and intranasal (<a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>), without similar route of administration in the controls. We judged nine other trials to have unclear risk of performance bias because there were insufficient details to infer who was blinded (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). </p> </section> <section id="CD006034-sec-0067"> <h5 class="title">Detection bias</h5> <p>We considered 16 trials to have high risk of detection bias because their assessments of bleeding and pain outcomes were subjective (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). In these trials, the participants assessed the outcome by filling in the questionnaires and PBACs and recording their symptoms in diaries. Four trials met the criteria for low risk of detection bias, with the use of alkaline hematin tests in laboratories (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). One trial had unclear risk of detection bias because they did not describe their methods of outcome measurement and there were no other details regarding blinding of outcome assessors (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>). </p> </section> </section> <section id="CD006034-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Eighteen trials had low risk of attrition bias because there were either no missing data or they excluded the missing data from analysis, or they applied the intention‐to‐treat principle (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). Three trials had unclear risk of attrition bias because they did not provide details regarding missing data (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). </p> </section> <section id="CD006034-sec-0069"> <h4 class="title">Selective reporting</h4> <p>The majority of the included trials published only data. There was no access to the trial registration reports or trial protocols. Under these conditions, we were not able to evaluate whether trial authors had overlooked reporting findings for all their pre‐specified outcomes. Thus, we considered 13 trials to have an unclear risk of reporting bias (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>; <a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>; <a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). The remaining eight trials met the criteria for low risk of reporting bias because they listed their pre‐specified outcomes in their protocols or trial registration reports (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>; <a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>; <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>; <a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>; <a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). </p> </section> <section id="CD006034-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>We deemed most of the included trials to have low risk of bias in this domain as they appeared free from other sources of bias. We judged one trial, which was a cross‐over design, to be high risk due to differences in baseline characteristics because four out of 10 participants on IUD had prolonged bleeding time, increased capillary fragility or a history of bleeding tendencies prior to intervention (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>). Two trials had unclear risk of bias because the baseline characteristics were not available (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>). </p> </section> </section> <section id="CD006034-sec-0071"> <h3 class="title" id="CD006034-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD006034-tbl-0001"><b>Summary of findings 1</b> Interventions (vitamin B1, mefenamic acid, tranexamic acid) compared to placebo or active comparators (desmopressin, sodium diclofenac, flavonoids) for the treatment of heavy menstrual bleeding associated with Cu IUD</a>; <a href="./full#CD006034-tbl-0002"><b>Summary of findings 2</b> Ulipristal acetate compared to placebo for the treatment of heavy menstrual bleeding associated with LNG IUD</a>; <a href="./full#CD006034-tbl-0003"><b>Summary of findings 3</b> Mefanamic acid compared to Vitex agnus for the treatment of heavy menstrual bleeding associated with unknown IUD type</a>; <a href="./full#CD006034-tbl-0004"><b>Summary of findings 4</b> Tranexamic acid compared to sodium diclofenac for the treatment of pain associated with Cu IUD</a>; <a href="./full#CD006034-tbl-0005"><b>Summary of findings 5</b> Naproxen compared to placebo for the treatment of pain associated with unknown IUD type</a>; <a href="./full#CD006034-tbl-0006"><b>Summary of findings 6</b> Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) compared to placebo or active comparators (paracetamol, tranexamic acid) for the prevention of heavy menstrual bleeding associated with Cu IUD</a>; <a href="./full#CD006034-tbl-0007"><b>Summary of findings 7</b> Interventions (ulipristal acetate, tranexamic acid, mifepristone, naproxen) compared placebo or active comparators (mefenamic acid, vitamin B, estradiol) for the prevention of heavy menstrual bleeding associated with LNG IUD</a>; <a href="./full#CD006034-tbl-0008"><b>Summary of findings 8</b> Interventions (ibuprofen, tolfenamic acid) compared to placebo for the prevention of pain associated with Cu IUD</a> </p> <section id="CD006034-sec-0072"> <h4 class="title">Primary outcomes</h4> <section id="CD006034-sec-0073"> <h5 class="title">Treatment trials</h5> <section id="CD006034-sec-0074"> <h6 class="title">Treatment of heavy menstrual bleeding associated with IUD use</h6> <section id="CD006034-sec-0075"> <p><b>Cu IUD</b></p> <p> <ul id="CD006034-list-0021"> <li> <p><b>Vitamin B1 versus placebo:</b> vitamin B1 may reduce the number of pads used per day (MD −7.0 pads, 95% CI −8.50 to −5.50, P &lt; 0.001; 1 trial, 110 participants; <a href="./references#CD006034-fig-0004" title="">Analysis 1.1</a>), number of spotting days (MD −1.60 days, 95% CI −1.94 to −1.26, P &lt; 0.001; 1 trial, 110 participants; <a href="./references#CD006034-fig-0005" title="">Analysis 1.2</a>) and number of bleeding days in comparison to placebo (MD −2.00 days, 95% CI −2.38 to −1.62; P &lt; 0.001; 1 trial, 110 participants; <a href="./references#CD006034-fig-0006" title="">Analysis 1.3</a>). This evidence was low certainty, downgraded for serious risk of bias and imprecision. </p> </li> <li> <p><b>Naproxen versus placebo:</b> there may be little or no difference between naproxen and placebo for heavier menstrual flow (OR 0.09, 95% CI 0.00 to 1.78; P = 0.11; 1 trial; 40 participants; <a href="./references#CD006034-fig-0007" title="">Analysis 2.1</a>) but the evidence is uncertain. The result was assessed as very low certainty, downgraded for very serious risk of bias and serious imprecision. </p> </li> <li> <p><b>Mefenamic acid versus tranexamic acid:</b> mefenamic acid may reduce the volume of menstrual blood loss in comparison to tranexamic acid (MD −64.26 mL, 95% CI −105.65 to −22.87; P = 0.002; 1 trial, 94 participants; <a href="./references#CD006034-fig-0004" title="">Analysis 1.1</a>). The certainty of evidence was low, downgraded for very serious risk of bias and serious imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). Mefenamic acid may have lower pictorial blood loss assessment chart (PBAC) score in contrast to tranexamic acid (MD −8.19, 95% CI −25.24 to 8.86; P = 0.35; 1 trial, 58 participants; <a href="./references#CD006034-fig-0010" title="">Analysis 3.2</a>) but the evidence is very uncertain. The certainty of evidence was very low, downgraded for very serious risk of bias and serious imprecision. There may be little or no difference in the number of bleeding days between mefenamic acid and tranexamic acid (MD 0.08 days, 95% CI −0.27 to 0.42; P = 0.66, I<sup>2</sup> = 0; 2 trials, 152 participants; <a href="./references#CD006034-fig-0011" title="">Analysis 3.3</a>). Evidence was of low certainty, downgraded for serious imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). </p> </li> <li> <p><b>Mefenamic acid versus desmopressin:</b> the evidence is very uncertain about the effect of mefenamic acid compared to desmopressin and there were insufficient data available for analysis. It was reported that the mean reduction in PBAC score was 45.7% in the mefenamic acid group and 40.5% in the desmopressin group (1 trial, 24 participants; <a href="./references#CD006034-fig-0012" title="">Analysis 4.1</a>). Evidence was very low certainty, downgraded due to very serious risk of bias and serious imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). </p> </li> <li> <p><b>Tranexamic acid versus sodium diclofenac:</b> tranexamic acid may reduce the volume of menstrual blood loss in comparison to sodium diclofenac (MD −42.70 mL, 95% CI −73.33 to −12.07; P = 0.006; 1 trial, 38 participants; <a href="./references#CD006034-fig-0014" title="">Analysis 5.1</a>) but the evidence is very low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). There may be little or no difference in the duration of bleeding between tranexamic acid and sodium diclofenac (MD 0.00 95% CI −0.62 to 0.62; P = 1.0; 1 trial, 38 participants; <a href="./references#CD006034-fig-0015" title="">Analysis 5.2</a>) but the evidence is very uncertain. Evidence was of very low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). </p> </li> <li> <p><b>Tranexamic acid versus flavonoids:</b> tranexamic acid may be associated with a modest reduction in PBAC score compared with oral flavonoids (MD −32.0, 95% CI −39.84 to −24.16; P &lt; 0.001; 1 trial, 100 participants; <a href="./references#CD006034-fig-0017" title="">Analysis 6.1</a>). The certainty of evidence was low, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). Tranexamic acid may result in fewer pads used per day (MD −0.50 pads, 95% CI −0.91 to −0.09; P = 0.02; 1 trial, 100 participants; <a href="./references#CD006034-fig-0018" title="">Analysis 6.2</a>) and fewer bleeding days in comparison to flavonoids (MD −1.40 days, 95% CI −1.93 to −0.87; 1 trial, 100 participants; <a href="./references#CD006034-fig-0019" title="">Analysis 6.3</a>). The certainty of evidence was assessed as low, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). </p> </li> <li> <p><b>Tranexamic acid versus active comparators (mefenamic acid, flavonoid, sodium diclofenac):</b> the evidence is very uncertain about the effect of tranexamic acid compared to controls in the number of bleeding days (MD −0.27 95% CI −1.14 to 0.60; P = 0.54, I<sup>2</sup> = 87%; 4 trials, 290 participants; <a href="./references#CD006034-fig-0021" title="">Analysis 7.1</a>). The certainty of evidence was very low, downgraded for serious risk of bias and inconsistency (<a href="./full#CD006034-tbl-0001">summary of findings Table 1</a>). This was a composite analysis as other trials had different interventions and outcomes, which could not be analysed together. </p> </li> </ul> </p> </section> <section id="CD006034-sec-0076"> <p><b>LNG IUD</b></p> <p> <ul id="CD006034-list-0022"> <li> <p><b>Ulipristal acetate versus placebo:</b> the evidence is very uncertain about the effect of ulipristal acetate compared with placebo on the duration of bleeding (MD −3.30 days, 95% CI −9.07 to 2.47; P = 0.26, 1 trial, 24 participants; <a href="./references#CD006034-fig-0022" title="">Analysis 8.1</a>) and number of bleeding days in 90 days (MD −9.30 days, 95% CI −26.76 to 8.16; P = 0.30, 1 trial, 24 participants; <a href="./references#CD006034-fig-0023" title="">Analysis 8.2</a>). This evidence was very low certainty, downgraded for serious risk of bias and serious imprecision as well as inconsistency (<a href="./full#CD006034-tbl-0002">summary of findings Table 2</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0077"> <p><b>Unknown IUD type</b></p> <p> <ul id="CD006034-list-0023"> <li> <p><b>High‐dose naproxen versus low‐dose naproxen:</b> the evidence is very uncertain about the effect of different naproxen doses on menstrual blood loss; there were insufficient data available for analysis. One trial involving 34 users of an unknown type of IUD reported that naproxen 1250 mg per day for five days had higher percentage (31.6%) of menstrual blood loss in comparison to 500 mg on day one then 750 mg per day for five days (9.5%) (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>; <a href="./references#CD006034-fig-0024" title="">Analysis 9.1</a>). </p> </li> <li> <p><b>Mefenamic acid versus Vitex agnus:</b> mefenamic acid may not differ from Vitex agnus in PBAC score (MD −2.40, 95% CI −13.77 to 8.97; P = 0.68; 1 trial, 84 participants; <a href="./references#CD006034-fig-0025" title="">Analysis 10.1</a>). The certainty of evidence was low, downgraded due to serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0003">summary of findings Table 3</a>). </p> </li> </ul> </p> </section> </section> <section id="CD006034-sec-0078"> <h6 class="title">Treatment of pain associated with IUD use</h6> <section id="CD006034-sec-0079"> <p><b>Cu IUD</b></p> <p> <ul id="CD006034-list-0024"> <li> <p><b>Tranexamic acid versus sodium diclofenac:</b> there may be little or no difference between tranexamic acid and sodium diclofenac for the occurrence of pelvic pain (OR 1.0, 95% CI 0.06 to 17.25; P = 1.00; 1 trial, 38 participants; <a href="./references#CD006034-fig-0027" title="">Analysis 11.1</a>) but the evidence is very uncertain. The evidence was very low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0004">summary of findings Table 4</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0080"> <p><b>Unknown IUD type</b></p> <p> <ul id="CD006034-list-0025"> <li> <p><b>Naproxen versus placebo:</b> compared to placebo, naproxen may be associated with lower overall pain relief scores (MD 4.1, 95% CI 0.91 to 7.29; P = 0.01; 1 trial, 33 participants; <a href="./references#CD006034-fig-0028" title="">Analysis 12.1</a>) and lower daily pain relief score (MD 3.1, 95% CI 0.27 to 5.93; P = 0.03; 1 trial, 33 participants; <a href="./references#CD006034-fig-0029" title="">Analysis 12.2</a>). Evidence for both outcomes was low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0005">summary of findings Table 5</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD006034-sec-0081"> <h5 class="title">Prevention trials</h5> <section id="CD006034-sec-0082"> <h6 class="title">Prevention of heavy menstrual bleeding associated with IUD use</h6> <section id="CD006034-sec-0083"> <p><b>Cu IUD</b></p> <p> <ul id="CD006034-list-0026"> <li> <p><b>Ibuprofen versus placebo:</b> the trial arms did not differ significantly in reduction of blood loss volume, measured by alkaline hematin method, for ibuprofen and placebo (MD −14mL.11, 95% CI −36.04 to 7.82; P = 0.21; 2 trials, 40 participants; <a href="./references#CD006034-fig-0032" title="">Analysis 13.1</a>). Subgroup analysis by type of IUD (Lippes loop and Cu IUD) also revealed no difference. The evidence was of low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0006">summary of findings Table 6</a>). In another trial (<a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>), there was no difference in duration of bleeding between ibuprofen and placebo (MD −0.20 days, 95% CI −1.40 to 1.00; P = 0.74; 1 trial; 28 participants; <a href="./references#CD006034-fig-0033" title="">Analysis 13.2</a>). The evidence was of very low certainty, downgraded for very serious risk of bias and serious imprecision (<a href="./full#CD006034-tbl-0006">summary of findings Table 6</a>). The median blood loss in this trial was 51 mL in the ibuprofen group with Fincoid IUD and 47 mL with the multiload copper‐375 IUD in comparison to 49 mL in the placebo group with Fincoid IUD and 62 mL with the multiload copper‐375 IUD (<a href="./references#CD006034-fig-0034" title="">Analysis 13.3</a>). </p> </li> <li> <p><b>Tolfenamic acid versus placebo:</b> tolfenamic acid resulted in fewer pads used per day (MD −1.00 pads, 95% CI −1.57 to −0.43; P &lt; 0.001; 1 trial, 122 participants; <a href="./references#CD006034-fig-0036" title="">Analysis 14.1</a>), fewer occurrences of menstruation that were "more abundant than normal" in comparison to placebo (OR 0.54, 95% CI 0.34 to 0.85; P = 0.008; 1 trial, 181 events; <a href="./references#CD006034-fig-0037" title="">Analysis 14.2</a>) and fewer blood clots (OR 0.43, 95% CI 0.27 to 0.68, P &lt; 0.001; 1 trial, 150 events; <a href="./references#CD006034-fig-0038" title="">Analysis 14.3</a>). Evidence was very low certainty; downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0006">summary of findings Table 6</a>). </p> </li> <li> <p><b>Aspirin versus paracetamol:</b> there was no evidence of a difference between aspirin and paracetamol to reduce the volume of menstrual blood loss (MD −0.30, 95% CI −26.16 to 25.56; P = 0.98; 1 trial, 20 participants; <a href="./references#CD006034-fig-0039" title="">Analysis 15.1</a>). This evidence was of very low certainty, downgraded for very serious risk of bias and serious imprecision (<a href="./full#CD006034-tbl-0006">summary of findings Table 6</a>). </p> </li> <li> <p><b>Higher dose of tranexamic acid versus lower dose of tranexamic acid:</b> one trial conducted among 175 Cu IUD users compared 1 g tranexamic acid to 2 g tranexamic acid for the prevention of bleeding (<a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>). The percentage occurrence of heavy menstrual bleeding was 20% in the 2 g tranexamic acid arm versus 11.76% in the 1 g tranexamic acid arm as measured by the alkaline hematin method (<a href="./references#CD006034-fig-0040" title="">Analysis 16.1</a>). The PBAC score was also lower in the 2 g tranexamic acid group (26.79%) in comparison to 1 g tranexamic acid (45.83%; <a href="./references#CD006034-fig-0040" title="">Analysis 16.1</a>). The evidence was very low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0006">summary of findings Table 6</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0084"> <p><b>LNG IUD</b></p> <p> <ul id="CD006034-list-0027"> <li> <p><b>Ulipristal acetate (CBD‐2914) versus placebo:</b> ulipristal acetate may increase the percentage bleeding or spotting days in comparison to placebo (MD 9.50, 95% CI 1.48 to 17.52; P = 0.02; 1 trial, 118 participants; <a href="./references#CD006034-fig-0041" title="">Analysis 17.1</a>). However, the certainty of evidence was low, downgraded for serious risk of bias and very serious imprecision (<a href="./full#CD006034-tbl-0007">summary of findings Table 7</a>). </p> </li> <li> <p><b>Tranexamic acid versus mefenamic acid and placebo:</b> one trial that compared tranexamic acid, mefenamic acid and placebo had insufficient data for analysis (<a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>). The median number of bleed days reported was 8 days in the tranexamic acid group, 10 in the mefenamic acid group and 11.5 in the placebo group (<a href="./references#CD006034-fig-0043" title="">Analysis 18.1</a>). Evidence was low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0007">summary of findings Table 7</a>). </p> </li> <li> <p><b>Mifepristone versus vitamin B:</b> there were insufficient data for analysis in the trial comparing mifepristone and vitamin B, which reported that fewer participants in the mifepristone group reported bleeding or spotting (<a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>; <a href="./references#CD006034-fig-0047" title="">Analysis 20.1</a>). The evidence was of very low certainty, downgraded for very serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0007">summary of findings Table 7</a>). </p> </li> <li> <p><b>Naproxen versus estradiol:</b> one trial provided insufficient data for analysis of number of bleeding days for naproxen compared with estradiol (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>). The median number of bleeding days in the naproxen arm was 27.5 in comparison to 44 days in the estradiol arm (<a href="./references#CD006034-fig-0044" title="">Analysis 19.1</a>). Evidence was very low certainty, downgraded for very serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0007">summary of findings Table 7</a>). </p> </li> </ul> </p> </section> </section> <section id="CD006034-sec-0085"> <h6 class="title">Prevention of pain</h6> <section id="CD006034-sec-0086"> <p><b>Cu IUD</b></p> <p> <ul id="CD006034-list-0028"> <li> <p><b>Tolfenamic acid versus placebo:</b> there may be little or no difference between tolfenamic acid and placebo in reduction of the occurrence of menstruation that was "more painful than normal" but the evidence is very uncertain (OR 0.71, 95% CI 0.44 to 1.14; P = 0.15; 1 trial, 108 events; <a href="./references#CD006034-fig-0048" title="">Analysis 21.1</a>). Evidence was very low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0008">summary of findings Table 8</a>). </p> </li> <li> <p><b>Ibuprofen versus placebo:</b> there may be little or no difference between ibuprofen and placebo in the reduction of menstrual cramps (OR 1.0, 95% CI 0.11 to 8.95, P = 1.00; 1 trial, 4 events; <a href="./references#CD006034-fig-0050" title="">Analysis 22.1</a>). The evidence was low certainty, downgraded for serious risk of bias and imprecision (<a href="./full#CD006034-tbl-0008">summary of findings Table 8</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD006034-sec-0087"> <h4 class="title">Secondary outcomes</h4> <section id="CD006034-sec-0088"> <h5 class="title">Treatment trials</h5> <section id="CD006034-sec-0089"> <h6 class="title">IUD removal</h6> <p>No treatment trials assessed IUD removal due to bleeding or pain.</p> </section> <section id="CD006034-sec-0090"> <h6 class="title">Haemoglobin levels</h6> <p>One trial reported on pre‐ and post‐haemoglobin levels of all Cu IUD participants, but data were insufficient for analysis because the trial did not compare tranexamic acid and sodium diclofenac (<a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). The mean (standard error) for pre‐intervention blood haemoglobin concentrations was 124.8 (1.9) g/L while for post‐intervention it was 124.7 (1.8) g/L. </p> </section> <section id="CD006034-sec-0091"> <h6 class="title">Need for additional analgesia</h6> <p>One trial that compared naproxen to placebo for the treatment of pain associated with IUD use (unknown type of IUD) reported the use of additional analgesia (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>). There was no difference between naproxen and placebo for the use of additional analgesia (OR 0.29, 95% CI 0.05 to 1.80; P = 0.19; 1 trial, 33 participants, 7 events; <a href="./references#CD006034-fig-0031" title="">Analysis 12.4</a>). </p> </section> <section id="CD006034-sec-0092"> <h6 class="title">Quality of life</h6> <p>No treatment trial reported quality of life.</p> </section> <section id="CD006034-sec-0093"> <h6 class="title">Side effects</h6> <p>Four treatment trials among Cu IUD users reported side effects but it was not possible to analyze the data due to differences in various side effects, interventions and control. In a small trial by <a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a>, it was difficult to estimate the difference between mefenamic acid and desmopressin, with no effect on the occurrence of headache and insomnia (OR 0.11, 95% CI 0.00 to 2.36, P = 016; 1 trial, 24 participants, 3 events; <a href="./references#CD006034-fig-0013" title="">Analysis 4.2</a>). </p> <p>In another trial that compared tranexamic acid and sodium diclofenac for the occurrence of side effects (gastrointestinal symptoms, headache, sweating), tranexamic acid increased the odds of the occurrence of side effects compared to sodium diclofenac (OR 4.69, 95% CI 1.20 to 18.44; P = 0.03; 1 trial, 38 participants, 19 events; <a href="./references#CD006034-fig-0016" title="">Analysis 5.3</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). </p> <p>The occurrence of headache (OR 0.58, 95% CI 0.18 to 1.92; P = 0.38; 1 trial, 100 participants, 13 events; <a href="./references#CD006034-fig-0020" title="">Analysis 6.4</a>) and vomiting (OR 0.74, 95% CI 0.25 to 2.18; P = 0.59; 1 trial, 100 participants, 16 events; <a href="./references#CD006034-fig-0020" title="">Analysis 6.4</a>) also did not differ in a trial comparing tranexamic acid and oral flavonoids (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>). </p> <p>There was also no difference in the occurrence of side effects in a trial that compared naproxen and placebo (OR 1.91, 95% CI 0.72 to 5.06; P = 0.19; 1 trial, 336 participants, 16 events; <a href="./references#CD006034-fig-0008" title="">Analysis 2.2</a>; <a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>). </p> <p>In another trial comparing mefenamic acid and Vitex agnus (<a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>), where the IUD type was not known, the occurrence of nausea (OR 1.00, 95% CI 0.06 to 16.53; P = 1.0; 1 trial, 84 participants, 2 events; <a href="./references#CD006034-fig-0026" title="">Analysis 10.2</a>) and abdominal pain (OR 0.33, 95% CI 0.01 to 8.22; P = 0.50; 1 trial; 84 participants, 1 event; <a href="./references#CD006034-fig-0026" title="">Analysis 10.2</a>) did not differ. </p> </section> </section> <section id="CD006034-sec-0094"> <h5 class="title">Prevention trials</h5> <section id="CD006034-sec-0095"> <h6 class="title">IUD removal</h6> <p>One prevention trial assessed the effect of ibuprofen and placebo among Cu IUD users on IUD removal due to pain or increased blood loss (<a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a>). There was no difference between ibuprofen and placebo on IUD removal due to pain or increased blood loss by 26 weeks (OR 0.96, 95% CI 0.66 to 1.38; P = 0.81; 1 trial, 1962 participants, 120 events; <a href="./references#CD006034-fig-0051" title="">Analysis 23.1</a>) and by 52 weeks (OR 1.25, 95% CI 0.39 to 1.69; P = 0.14; 1 trial, 1962 participants, 190 events; <a href="./references#CD006034-fig-0052" title="">Analysis 23.2</a>). </p> </section> <section id="CD006034-sec-0096"> <h6 class="title">Haemoglobin levels</h6> <p>No prevention trial assessed haemoglobin levels.</p> </section> <section id="CD006034-sec-0097"> <h6 class="title">Need for additional analgesia</h6> <p>No prevention trial assessed need for analgesia.</p> </section> <section id="CD006034-sec-0098"> <h6 class="title">Quality of life</h6> <p>No prevention trial assessed quality of life.</p> </section> <section id="CD006034-sec-0099"> <h6 class="title">Side effects</h6> <p>Four prevention trials provided data for side effects but it was not feasible to pool data for analysis due to differences in side effects, interventions and control. Three trials were in Cu IUD users (<a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>; <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>), while one trial was among LNG IUD users (<a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a>). There was no difference in the occurrence of side effects between ibuprofen and placebo in two trials (OR 2.15, 95% CI 0.5 to 9.31; P = 0.30, I<sup>2</sup> = 0%; 2 trials, 108 participants, 8 events; <a href="./references#CD006034-fig-0035" title="">Analysis 13.4</a>; <a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>; <a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>). </p> <p>In another trial comparing tolfenamic acid and placebo (<a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>), there was no difference in the occurrence of side effects (OR 0.42, 95% CI 0.02 to 9.29; P = 0.58; 1 trial, 366 participants, 14 events; <a href="./references#CD006034-fig-0049" title="">Analysis 21.2</a>). The occurrence of dyspepsia and diarrhoea (OR 9.96, 95% CI 0.52 to 189.04; P = 0.13; 1 trial, 122 participants, 4 events; <a href="./references#CD006034-fig-0049" title="">Analysis 21.2</a>) were more common with tolfenamic acid but the estimate was not statistically significant and the confidence interval was wide. The occurrence of headache (OR 0.09, 95% CI 0.00 to 1.60; P = 0.10; 1 trial, 122 participants, 5 events; <a href="./references#CD006034-fig-0049" title="">Analysis 21.2</a>) and depression (OR 0.09, 95% CI 0.00 to 1.60, P = 0.10; 1 trial, 122 participants, 5 events; <a href="./references#CD006034-fig-0049" title="">Analysis 21.2</a>) did not differ between tolfenamic acid and placebo. </p> <p>There was no difference in the occurrence of gastroesophageal reflux between naproxen and estradiol among LNG IUD users (OR 3.22, 95% CI 0.13 to 81.19; P = 0.48; 1 trial, 86 participants, 1 event; <a href="./references#CD006034-fig-0046" title="">Analysis 19.3</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006034-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006034-sec-0100"></div> <section id="CD006034-sec-0101"> <h3 class="title" id="CD006034-sec-0101">Summary of main results</h3> <p>This updated review includes 21 trials involving 3689 participants. Trials were mostly conducted in upper‐middle‐ to high‐income countries. There were 11 treatment trials (seven Cu IUD, one LNG IUD, three unknown IUD type), involving 767 participants, and 10 prevention trials (six Cu IUD, four LNG IUD), involving 2922 participants. This review has also extended its interventions to not just include NSAIDs but any interventions that were assessed to treat or prevent heavy menstrual bleeding or pain, or both, induced by IUD. </p> <section id="CD006034-sec-0102"> <h4 class="title">Treatment trials</h4> <section id="CD006034-sec-0103"> <h5 class="title">Treatment of heavy menstrual bleeding associated with Cu IUD use</h5> <p> <ul id="CD006034-list-0029"> <li> <p><b>Vitamin B1 versus placebo:</b> in one trial involving 126 participants, 100 mg vitamin B1 may reduce the number of pads used per day, number of spotting days and duration of bleeding in comparison to placebo (<a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a>). Since the evidence was from one trial, we cannot draw definitive conclusions. </p> </li> <li> <p><b>Naproxen versus placebo:</b> there may be little or no difference between oral naproxen (500 mg followed by 250 mg two to four times per day as needed) and oral placebo in the amount of menstrual flow according to one small trial involving 40 participants but the effect is very uncertain (<a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a>). </p> </li> <li> <p><b>Mefenamic acid versus tranexamic acid:</b> oral mefenamic acid at 1500 mg per day may reduce the volume of menstrual blood loss in comparison to oral tranexamic acid 1500 mg per day but this evidence is based on one trial with 94 participants, thus, we cannot draw definitive conclusions (<a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>). Mefenamic acid and tranexamic acid may not reduce the duration of bleeding (<a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>). This evidence however, was based on two trials involving a total of 152 participants. </p> </li> <li> <p><b>Mefenamic acid versus desmopressin:</b> there were insufficient data for analysis. </p> </li> <li> <p><b>Tranexamic acid versus sodium diclofenac:</b> based on one trial involving 38 participants (<a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>), oral tranexamic acid at 4.5 g per day for five days may reduce the volume of menstrual blood loss but not the duration of bleeding in comparison to oral sodium diclofenac 150 mg on day 1 then 75 mg for four days. </p> </li> <li> <p><b>Tranexamic acid versus flavonoids:</b> oral tranexamic acid 500 mg, six‐hourly, taken for the first three days of menstruation, had a lower PBAC score, fewer number of pads used per day and fewer bleeding days in comparison to flavonoids. This evidence was also from a single trial involving 100 participants (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>). </p> </li> <li> <p><b>Tranexamic acid versus comparisons:</b> oral tranexamic acid (at various doses and regimes) may reduce the number of bleeding days in comparison to control (<a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a>; <a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a>; <a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a>; <a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). There was substantial heterogeneity due to the various doses of tranexamic acid and type of comparisons used (mefenamic acid, flavonoid, sodium diclofenac). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0104"> <h5 class="title">Treatment of heavy menstrual bleeding associated with LNG IUD use</h5> <p> <ul id="CD006034-list-0030"> <li> <p><b>Ulipristal acetate versus placebo:</b> oral ulipristal acetate 5 mg per day taken for five days made no difference in comparison to placebo to the duration of days until bleeding stops and total bleeding days in 90 days for bleeding associated with LNG IUD use. However, this evidence was also from one small trial involving 30 participants (<a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0105"> <h5 class="title">Treatment of heavy menstrual bleeding associated with unknown IUD type</h5> <p> <ul id="CD006034-list-0031"> <li> <p><b>Higher dose naproxen versus lower dose naproxen:</b> there were insufficient data for analysis. One trial (<a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a>), compared oral naproxen 1250 mg per day for five days to 500 mg then 750 mg for five days and reported that the higher dose of naproxen reduced menstrual blood loss more than the lower dose (32% versus 22%). </p> </li> <li> <p><b>Mefenamic acid versus Vitex agnus:</b> the PBAC score did not differ significantly between oral mefenamic acid and Vitex agnus for the treatment of bleeding associated with LNG IUD based on one trial involving 84 participants (<a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0106"> <h5 class="title">Treatment of pain associated with Cu IUD use</h5> <p> <ul id="CD006034-list-0032"> <li> <p><b>Tranexamic acid versus sodium diclofenac:</b> there was no difference between oral tranexamic acid and oral sodium diclofenac for pain in one trial involving 38 participants (<a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0107"> <h5 class="title">Treatment of pain associated with unknown IUD type</h5> <p> <ul id="CD006034-list-0033"> <li> <p><b>Naproxen versus placebo:</b> oral naproxen may provide overall and daily pain relief in comparison to placebo, but this evidence was also based on one trial with 33 participants thus definitive conclusions can’t be drawn (<a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a>). </p> </li> </ul> </p> </section> </section> <section id="CD006034-sec-0108"> <h4 class="title">Prevention trials</h4> <section id="CD006034-sec-0109"> <h5 class="title">Prevention of heavy menstrual bleeding associated with Cu IUD use</h5> <p> <ul id="CD006034-list-0034"> <li> <p><b>Ibuprofen versus placebo:</b> prophylactic oral ibuprofen did not reduce menstrual blood loss (<a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>) or duration of bleeding (<a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a>). There were insufficient data to pool these two trials together for further analysis. </p> </li> <li> <p><b>Tolfenamic acid versus placebo:</b> prophylactic tolfenamic acid at a dose of 600 mg per day may be effective to reduce the number of pads used, the number of occurrences of menstruation that were "more abundant than normal" and blood clots compared to placebo. The evidence was from one trial with 160 participants (<a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>). </p> </li> <li> <p><b>Aspirin versus paracetamol:</b> there was no significant difference between oral aspirin and oral paracetamol for the prevention of bleeding associated with Cu IUD, based on one small trial involving 20 participants (<a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a>). </p> </li> <li> <p><b>Higher dose of tranexamic acid versus lower dose of tranexamic acid:</b> there were insufficient data for analysis. One trial, involving 175 participants, compared 2 g prophylactic oral tranexamic acid versus 1 g and reported a lower percentage of heavy menstrual bleeding occurrence in the 2 g arm than in the 1 g arm (20% versus 11.76% via alkaline hematin method and 26.79% versus 45.83% via PBAC score; <a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a>). </p> </li> </ul> </p> </section> <section id="CD006034-sec-0110"> <h5 class="title">Prevention of bleeding associated with LNG IUD</h5> <p> <ul id="CD006034-list-0035"> <li> <p><b>Ulipristal acetate (CBD‐2914) versus placebo:</b> ulipristal acetate, a selective progesterone receptor modulator at a dose of 50 mg per day taken for three consecutive days with separate treatments starting from 21, 49 and 77 days after IUD insertion may not be effective to reduce the percentage bleeding/spotting days. This evidence was generated from a single trial involving 118 participants (<a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a>). </p> </li> <li> <p><b>Tranexamic acid versus mefenamic acid and placebo:</b> there were insufficient data for analysis. One trial including 187 participants (<a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a>), reported that the median number of bleed days in the prophylactic tranexamic acid group was 8 days while in the mefenamic acid group it was 10 days, and 11.5 days with placebo. </p> </li> <li> <p><b>Mifepristone versus vitamin B:</b> there were insufficient data for analysis in the trial comparing prophylactic mifepristone and vitamin B (<a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a>). </p> </li> <li> <p><b>Naproxen versus estradiol:</b> there were insufficient data for analysis. The median number of bleeding days in the naproxen arm was 27.5 in comparison to 44 days in the estradiol arm from the trial conducted by <a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a> involving 129 women. The occurrence of gastroesophageal reflux was more common in the naproxen group but findings were not statistically significant with a wide confidence interval. </p> </li> </ul> </p> </section> <section id="CD006034-sec-0111"> <h5 class="title">Prevention of pain associated with Cu IUD use</h5> <p> <ul id="CD006034-list-0036"> <li> <p><b>Tolfenamic acid versus placebo:</b> there was no difference between prophylactic oral tolfenamic acid and placebo in the occurrence of more painful menstruation among 160 Cu IUD users in one trial conducted by <a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a>. </p> </li> <li> <p><b>Ibuprofen versus placebo:</b> there was also no difference in oral ibuprofen and placebo to prevent menstrual cramps associated with Cu IUD use. This evidence was from one small trial involving 20 participants (<a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a>) thus, further research is necessary. </p> </li> </ul> </p> </section> </section> </section> <section id="CD006034-sec-0112"> <h3 class="title" id="CD006034-sec-0112">Overall completeness and applicability of evidence</h3> <p>This review included a heterogeneous literature due to the broad review objective and scope. The heterogeneity related to the intent of the intervention either for prophylaxis or treatment, the various interventions and comparators, the different intervention regimens, reporting of outcomes and limited number of trials, and the different IUD types studied. Due to the considerable heterogeneity we could not combine the data using meta‐analysis. Therefore, the overall completeness of evidence in this review is limited. </p> <p>In terms of applicability in clinical practice based on evidence in this review, there is still insufficient evidence to draw conclusions regarding a specific drug or regimen for the treatment or prevention of heavy menstrual bleeding or pain associated with IUD use. In agreement with the previous review, mefenamic acid and tranexamic acid may reduce heavy menstrual bleeding associated with Cu IUD use. Vitamin B1 may reduce heavy menstrual bleeding while naproxen may reduce pain among Cu IUD users. Prophylactic tolfenamic acid could possibly reduce heavy menstrual bleeding associated with Cu IUD use. There was no evidence for the effectiveness of ulipristal and Vitex agnus to treat bleeding and pain associated with LNG IUD and ulipristal acetate to prevent heavy menstrual bleeding. </p> <p>With regard to side effects, there were only two trials that had sufficient data for analysis. The occurrence of dyspepsia and headache was more frequent with tolfenamic acid while gastroesophageal reflux was more common with naproxen. The evidence for side effects was limited, with wide confidence intervals. It was not possible to rule out possible harms and establish the side effects of treatments. </p> </section> <section id="CD006034-sec-0113"> <h3 class="title" id="CD006034-sec-0113">Quality of the evidence</h3> <p>We used GRADE to evaluate the certainty of evidence for each primary and secondary outcome, as reported in the summary of findings tables. The methodological quality of the evidence varied from very low to low. The major limitations were risk of bias and imprecision. Risk of bias was mostly serious due to unclear selection (allocation concealment), detection (unclear blinding of outcome assessors and self‐reporting of subjective assessments such as pain) and reporting bias (unpublished protocols). Most of the evidence had serious imprecision as effect measures were mostly obtained from a single trial for each of the comparisons. Larger, properly designed trials of the interventions are essential in order to achieve conclusions on the comparative efficacy of treatments. </p> </section> <section id="CD006034-sec-0114"> <h3 class="title" id="CD006034-sec-0114">Potential biases in the review process</h3> <p>We are mindful of possible biases in the reviewing process and have undertaken several measures to curb bias, such as having two review authors independently extracting data. Publication of an updated protocol prior to undertaking this review would have been better but all review authors have approved the protocol changes prior to initiating the review. We deem that all relevant trials are now incorporated but cannot dismiss the likelihood that additional trials may be unpublished or published in sources not accessible to our search. Hence, publication bias cannot be wholly disregarded. </p> </section> <section id="CD006034-sec-0115"> <h3 class="title" id="CD006034-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>There are several systematic reviews previously published for pain and bleeding unrelated to IUD use. There was insufficient evidence to determine whether NSAIDs reduced volumes of menstrual blood loss in comparison to combined oral contraceptives for heavy menstrual bleeding unrelated to IUD use (<a href="./references#CD006034-bbs2-0058" title="LethabyA , WiseMR , WeteringsMA , Bofill RodriguezM , BrownJ . Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD000154. [DOI: 10.1002/14651858.CD000154.pub3]">Lethaby 2019</a>). In another systematic review for participants with primary pain, NSAIDs were effective for pain relief but had more side effects particularly gastrointestinal symptoms (<a href="./references#CD006034-bbs2-0062" title="MarjoribanksJ , AyelekeRO , FarquharC , ProctorM . Nonsteroidal anti‐inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD001751. [DOI: 10.1002/14651858.CD001751.pub3]">Marjoribanks 2015</a>). We found low‐ to very low‐certainty evidence that mefenamic acid, tranexamic acid and vitamin B1 may reduce heavy menstrual bleeding associated with Cu IUD use, while naproxen may relieve pain. </p> <p>Trials investigating NSAIDs in this review had various interventions and outcome measures. Thus, no conclusions can be drawn regarding the preferred NSAID. There is limited evidence in terms of the possible effectiveness of NSAIDs, or whether a specific NSAID or regimen might be most effective to reduce pain associated with IUD use. Therefore, the choice of NSAID might be driven by other considerations such as cost, dosage and regimen, drug interactions, and patient’s preference, as well as side effects. </p> <p>Research regarding the interventions to treat and prevent heavy bleeding and pain associated with LNG IUD use remains limited. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006034-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram" data-id="CD006034-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials" data-id="CD006034-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial" data-id="CD006034-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin B1 vs placebo (Cu IUD, treatment for HMB), Outcome 1: Number of pads/day" data-id="CD006034-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Vitamin B1 vs placebo (Cu IUD, treatment for HMB), Outcome 1: Number of pads/day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin B1 vs placebo (Cu IUD, treatment for HMB), Outcome 2: Number of spotting days" data-id="CD006034-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Vitamin B1 vs placebo (Cu IUD, treatment for HMB), Outcome 2: Number of spotting days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin B1 vs placebo (Cu IUD, treatment for HMB), Outcome 3: Number of bleeding days" data-id="CD006034-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Vitamin B1 vs placebo (Cu IUD, treatment for HMB), Outcome 3: Number of bleeding days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt='Comparison 2: Naproxen vs placebo (Cu IUD, treatment for HMB), Outcome 1: "More" menstrual flow' data-id="CD006034-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Naproxen vs placebo (Cu IUD, treatment for HMB), Outcome 1: "More" menstrual flow </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naproxen vs placebo (Cu IUD, treatment for HMB), Outcome 2: Side effects" data-id="CD006034-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Naproxen vs placebo (Cu IUD, treatment for HMB), Outcome 2: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB), Outcome 1: Volume of blood loss" data-id="CD006034-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB), Outcome 1: Volume of blood loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB), Outcome 2: PBAC score" data-id="CD006034-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB), Outcome 2: PBAC score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB), Outcome 3: Number of bleeding days" data-id="CD006034-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB), Outcome 3: Number of bleeding days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0012"> <p> <div class="table" id="CD006034-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Mean reduction of PBAC score (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>desmopressin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mefenamic acid</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mercorio 2003</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.7</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Mefenamic acid vs desmopressin (Cu IUD, treatment for HMB), Outcome 1: Mean reduction of PBAC score (%) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0012">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mefenamic acid vs desmopressin (Cu IUD, treatment for HMB), Outcome 2: Side effects: headache and insomnia" data-id="CD006034-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Mefenamic acid vs desmopressin (Cu IUD, treatment for HMB), Outcome 2: Side effects: headache and insomnia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB), Outcome 1: Menstrual blood loss (alkaline hematin)" data-id="CD006034-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB), Outcome 1: Menstrual blood loss (alkaline hematin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB), Outcome 2: Duration of menstruation" data-id="CD006034-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB), Outcome 2: Duration of menstruation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB), Outcome 3: Side effects" data-id="CD006034-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB), Outcome 3: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 1: PBAC score" data-id="CD006034-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 1: PBAC score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 2: Number of pads/day" data-id="CD006034-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 2: Number of pads/day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 3: Number of bleeding days" data-id="CD006034-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 3: Number of bleeding days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 4: Side effects" data-id="CD006034-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB), Outcome 4: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Tranexamic acid vs active comparators (mefenamic acid, flavonoids, diclofenac) (Cu IUD, treatment for HMB), Outcome 1: Number of bleeding days" data-id="CD006034-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Tranexamic acid vs active comparators (mefenamic acid, flavonoids, diclofenac) (Cu IUD, treatment for HMB), Outcome 1: Number of bleeding days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Ulipristal acetate vs placebo (LNG IUD, treatment of HMB), Outcome 1: Duration of days until bleeding stops" data-id="CD006034-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Ulipristal acetate vs placebo (LNG IUD, treatment of HMB), Outcome 1: Duration of days until bleeding stops </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Ulipristal acetate vs placebo (LNG IUD, treatment of HMB), Outcome 2: Total bleeding in 90 days" data-id="CD006034-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Ulipristal acetate vs placebo (LNG IUD, treatment of HMB), Outcome 2: Total bleeding in 90 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0024"> <p> <div class="table" id="CD006034-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood loss reduction (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>High dose naproxen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Low dose naproxen</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Davies 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: High‐dose naproxen vs low‐dose naproxen (unknown IUD, treatment of HMB), Outcome 1: Blood loss reduction (%) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Mefenamic acid vs Vitex agnus (unknown IUD, treatment for HMB), Outcome 1: PBAC score" data-id="CD006034-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Mefenamic acid vs Vitex agnus (unknown IUD, treatment for HMB), Outcome 1: PBAC score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Mefenamic acid vs Vitex agnus (unknown IUD, treatment for HMB), Outcome 2: Side effects" data-id="CD006034-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Mefenamic acid vs Vitex agnus (unknown IUD, treatment for HMB), Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for pain), Outcome 1: Pelvic pain" data-id="CD006034-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for pain), Outcome 1: Pelvic pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 1: Overall pain relief score" data-id="CD006034-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 1: Overall pain relief score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 2: Daily pain relief score" data-id="CD006034-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 2: Daily pain relief score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 3: Pain relief" data-id="CD006034-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 3: Pain relief </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 4: Need for analgesia" data-id="CD006034-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Naproxen vs placebo (unknown IUD, treatment for pain), Outcome 4: Need for analgesia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 1: Menstrual blood loss (alkaline hematin)" data-id="CD006034-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 1: Menstrual blood loss (alkaline hematin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 2: Duration of bleeding" data-id="CD006034-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 2: Duration of bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0034"> <p> <div class="table" id="CD006034-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Median menstrual blood loss (alkaline hematin)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ibuprofen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Fincoid</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Makarainen 1986</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ML Cu 375</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Makarainen 1986</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 3: Median menstrual blood loss (alkaline hematin) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0034">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 4: Side effects" data-id="CD006034-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Ibuprofen vs placebo (Cu IUD, prevention of HMB), Outcome 4: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Tolfenamic vs placebo (Cu IUD, prevention of HMB), Outcome 1: Number of pads/day" data-id="CD006034-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Tolfenamic vs placebo (Cu IUD, prevention of HMB), Outcome 1: Number of pads/day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt='Comparison 14: Tolfenamic vs placebo (Cu IUD, prevention of HMB), Outcome 2: Menstruation "more abundant than normal"' data-id="CD006034-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Tolfenamic vs placebo (Cu IUD, prevention of HMB), Outcome 2: Menstruation "more abundant than normal" </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Tolfenamic vs placebo (Cu IUD, prevention of HMB), Outcome 3: Clots in menstrual blood" data-id="CD006034-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Tolfenamic vs placebo (Cu IUD, prevention of HMB), Outcome 3: Clots in menstrual blood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Aspirin vs paracetamol (Cu IUD, prevention of HMB), Outcome 1: Menstrual blood loss (alkaline hematin)" data-id="CD006034-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Aspirin vs paracetamol (Cu IUD, prevention of HMB), Outcome 1: Menstrual blood loss (alkaline hematin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0040"> <p> <div class="table" id="CD006034-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Occurence of HMB (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2g tranexamic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1g tranexamic</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Alkaline hematin</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lin 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>PBAC</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lin 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.83</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: 2 g tranexamic vs 1 g tranexamic (Cu IUD, prevention HMB), Outcome 1: Occurence of HMB (%) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0040">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Ulipristal acetate (CDB‐2914) vs placebo (LNG IUD, prevention of HMB), Outcome 1: Percentage days bleeding or spotting" data-id="CD006034-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Ulipristal acetate (CDB‐2914) vs placebo (LNG IUD, prevention of HMB), Outcome 1: Percentage days bleeding or spotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Ulipristal acetate (CDB‐2914) vs placebo (LNG IUD, prevention of HMB), Outcome 2: Longest consecutive run of days without bleeding or spotting" data-id="CD006034-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Ulipristal acetate (CDB‐2914) vs placebo (LNG IUD, prevention of HMB), Outcome 2: Longest consecutive run of days without bleeding or spotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0043"> <p> <div class="table" id="CD006034-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Median number of bleeding days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>tranexamic acid (n=55)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mefenamic acid (n=57)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>placebo (n=56)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sordal 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Tranexamic acid vs mefenamic acid (LNG IUD, prevention of HMB), Outcome 1: Median number of bleeding days </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0043">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0044"> <p> <div class="table" id="CD006034-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Median number of bleeding and spotting days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Naproxen (n=35)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Estradiol (n=34)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n=37)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Madden 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Naproxen vs estradiol (LNG IUD, prevention of HMB), Outcome 1: Median number of bleeding and spotting days </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0044">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Naproxen vs estradiol (LNG IUD, prevention of HMB), Outcome 2: Satisfied with bleeding pattern at 12 weeks" data-id="CD006034-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: Naproxen vs estradiol (LNG IUD, prevention of HMB), Outcome 2: Satisfied with bleeding pattern at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Naproxen vs estradiol (LNG IUD, prevention of HMB), Outcome 3: Side effects" data-id="CD006034-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: Naproxen vs estradiol (LNG IUD, prevention of HMB), Outcome 3: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0047"> <p> <div class="table" id="CD006034-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Percentage bleeding and spotting days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mifepristone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vitamin B</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Papaikonomou 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fewer women reported bleeding or spotting. Less days with normal or heavy intensity bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More bleeding or spotting days.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Mifepristone vs vitamin B (LNG IUD, prevention of HMB), Outcome 1: Percentage bleeding and spotting days </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006034-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt='Comparison 21: Tolfenamic acid vs placebo (Cu IUD, prevention of pain), Outcome 1: Menstruation "more painful than normal"' data-id="CD006034-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Tolfenamic acid vs placebo (Cu IUD, prevention of pain), Outcome 1: Menstruation "more painful than normal" </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Tolfenamic acid vs placebo (Cu IUD, prevention of pain), Outcome 2: Side effects" data-id="CD006034-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: Tolfenamic acid vs placebo (Cu IUD, prevention of pain), Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Ibuprofen vs placebo (Cu IUD, prevention of pain), Outcome 1: Reduction in menstrual cramps" data-id="CD006034-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Ibuprofen vs placebo (Cu IUD, prevention of pain), Outcome 1: Reduction in menstrual cramps </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Ibuprofen vs placebo (Cu IUD,prevention of bleed and pain, IUD removal), Outcome 1: IUD removal by 26 weeks due to pain or increased blood loss" data-id="CD006034-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Ibuprofen vs placebo (Cu IUD,prevention of bleed and pain, IUD removal), Outcome 1: IUD removal by 26 weeks due to pain or increased blood loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006034-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/urn:x-wiley:14651858:media:CD006034:CD006034-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Ibuprofen vs placebo (Cu IUD,prevention of bleed and pain, IUD removal), Outcome 2: IUD removal due to pain or increased blood loss by 52 weeks" data-id="CD006034-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_t/tCD006034-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: Ibuprofen vs placebo (Cu IUD,prevention of bleed and pain, IUD removal), Outcome 2: IUD removal due to pain or increased blood loss by 52 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/media/CDSR/CD006034/image_n/nCD006034-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Interventions (vitamin B1, mefenamic acid, tranexamic acid) compared to placebo or active comparators (desmopressin, sodium diclofenac, flavonoids) for the treatment of heavy menstrual bleeding associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interventions versus comparisons</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Vitamin B1 vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Number of pads (diary record)</p> <p>Follow‐up: 1 month after completion of intervention for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of pads was <b>19 pads</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>7 pads fewer</b><br/>(8.5 fewer to 5.5 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days</p> <p>(diary record)</p> <p> </p> <p>Follow‐up: 1 month after completion of intervention for three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of bleeding was <b>8</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>2 days fewer</b><br/>(2.38 fewer to 1.62 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mefenamic acid vs tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Volume blood loss (pictorial chart in mL)</p> <p> </p> <p>Follow‐up: after 3rd month of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean volume of menstrual blood loss was <b>160 mL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>64.26 mL lower</b><br/>(105.65 lower to 22.87 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days (menstrual record)</p> <p> </p> <p>Follow‐up: after 3rd month of intervention</p> <p>Recorded on daily diary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of bleeding days was <b>3.5 to 6.4 days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.08 days more</b><br/>(0.27 fewer to 0.42 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mefenamic acid vs desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Mean reduction of PBAC score</p> <p>Follow‐up: after 3rd month of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>The mean reduction of PBAC score was 40.5% in desmopressin and 45.7% in mefenamic acid </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>b,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs sodium diclofenac</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Volume of blood loss (alkaline hematin method)</p> <p>Follow‐up: each intervention cycle (cross‐over) for 5 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss was <b>102</b>mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>42.7mL lower</b><br/>(73.33 lower to 12.07 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>c,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p> </p> <p>Follow‐up: each intervention cycle (cross‐over) for 5 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of bleeding was <b>5.1</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0 days </b><br/>(0.62 lower to 0.62 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>b,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastrointestinal disturbances (diarrhoea, lower abdominal pain), headache and sweating </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>316 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>684 per 1000 (356 to 895)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 4.69</p> <p>(1.2 to 18.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>b,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs flavonoids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>PBAC score</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score was <b>125</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>32 lower</b><br/>(39.84 lower to 24.16 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Number of pads per day</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of pads was <b>3</b> pads per day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.5 pads lower</b><br/>(0.91 lower to 0.09 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of bleed days was <b>6.8</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.4 days lower</b><br/>(1.93 lower to 0.87 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: headache </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 per 1000 (33 to 268)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.58 (0.18 to 1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: vomiting </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000 (33 to 268)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74 (0.25 to 2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>b,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs active comparators (mefenamic acid, flavonoid, sodium diclofenac)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Number of bleeding days</p> <p>Follow‐up: 2‐5 menstrual cycles</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of bleeding days was <b>5.1 to 6.8</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.27 days lower</b><br/>(1.14 lower to 0.6 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>f,h</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>PBAC:</b> pictorial blood assessment chart; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to unclear risk of selection bias.<br/><sup>b</sup>Downgraded one level for imprecision as effects were measured by one trial.<br/><sup>c</sup>Downgraded two levels for imprecision as effects were measured by one trial and the confidence interval was wide.<br/><sup>d</sup>Downgraded two levels due to unclear risk of selection bias and high risk of detection bias.<br/><sup>e</sup>Downgraded two levels due to high risk of performance bias and detection bias.<br/><sup>f</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias and high risk of detection bias.<br/><sup>g</sup>Downgraded one level due to high risk of detection bias.<br/><sup>h</sup>Downgraded one level for inconsistency due to high statistical heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Interventions (vitamin B1, mefenamic acid, tranexamic acid) compared to placebo or active comparators (desmopressin, sodium diclofenac, flavonoids) for the treatment of heavy menstrual bleeding associated with Cu IUD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ulipristal acetate compared to placebo for the treatment of heavy menstrual bleeding associated with LNG IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interventions vs comparisons</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ulipristal acetate vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Total bleeding in 90 days (bleeding calendar)</p> <p>Follow‐up: 30, 60 and 90 days after treatment initiation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean total of bleeding days in 90 days was <b>29.8 to 39.1</b> days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>9.3 days lower</b><br/>(26.76 lower to 8.16 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to high risk of detection bias.<br/><sup>b</sup>Downgraded two levels for imprecision as effects were only measured from one trial with small number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ulipristal acetate compared to placebo for the treatment of heavy menstrual bleeding associated with LNG IUD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mefanamic acid compared to Vitex agnus for the treatment of heavy menstrual bleeding associated with unknown IUD type</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interventions vs comparisons</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Mefenamic acid vs Vitex agnus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>PBAC score</p> <p>Follow‐up: monthly for 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score was <b>89.7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.4 lower</b><br/>(13.77 lower to 8.97 higher </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: nausea </p> <p>Follow‐up: monthly for 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> (1 to 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>OR 1.00 (0.06 to 16.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects</b>: abdominal pain </p> <p>Follow‐up: monthly for 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (0 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>OR 0.33 (0.01 to 8.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>c</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>PBAC:</b> pictorial blood assessment chart; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to unclear reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as effects were measured by only one trial.<br/><sup>c</sup>Downgraded two levels for imprecision as effects were measured from only one trial and confidence interval was wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mefanamic acid compared to Vitex agnus for the treatment of heavy menstrual bleeding associated with unknown IUD type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tranexamic acid compared to sodium diclofenac for the treatment of pain associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs sodium diclofenac</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pelvic pain</b> </p> <p>Follow‐up: each intervention cycle (cross over) for 5 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 per</b> 1000<br/>(3 to 489) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.06 to 17.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias and high risk of detection bias.<br/><sup>b</sup>Downgraded one level for imprecision as effect measures were from one small trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tranexamic acid compared to sodium diclofenac for the treatment of pain associated with Cu IUD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Naproxen compared to placebo for the treatment of pain associated with unknown IUD type</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naproxen vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall pain relief score</b> (4‐point scale) </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean overall pain relief score was <b>7.9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>4.1 higher</b><br/>(0.91 higher to 7.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily pain relief score</b> (6‐point scale) </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean daily pain relief score was <b>10.8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.1 higher</b><br/>(0.27 higher to 5.93 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for additional analgesia</b> (self‐recorded) </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>116 per</b> 1000<br/>(22 to 450) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.29</b><br/>(0.05 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastrointestinal symptoms </p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> (9 to 557) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.11 (0.18 to 25.17)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias as well as high risk of detection bias.<br/><sup>b</sup>Downgraded one level for imprecision as effect measures were from one small trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Naproxen compared to placebo for the treatment of pain associated with unknown IUD type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) compared to placebo or active comparators (paracetamol, tranexamic acid) for the prevention of heavy menstrual bleeding associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ibuprofen vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> (alkaline hematin method) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss was <b>44.7 to 109.2 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 14.11 mL lower</b><br/>(36.04 lower to 7.82 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> (menstrual diary) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of bleed was <b>6.4</b> days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.2 days lower</b><br/>(0.14 lower to 1 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> eye and mouth swelling, stomach cramps, fatigue, irritability (diary record) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> (20 to 271) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.15</b> (0.5 to 9.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tolfenamic acid vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>Menstruation "more abundant than normal"</p> <p>(questionnaire)</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per</b> 1000<br/>(396 to 621) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b><br/>(0.34 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> dyspepsia, diarrhoea, headache, fatigue </p> <p>(questionnaire)</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per</b> 1000<br/>(20 to 200) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.48</b><br/>(0.14 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aspirin vs paracetamol</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> (alkaline hematin method) </p> <p>Follow‐up: 3 cycles</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss was <b>49.5 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.3mL lower</b><br/>(26.16 lower to 25.56 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,f</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>2 g tranexamic acid vs 1 g tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>% occurrence of heavy menstrual bleeding (alkaline hematin method)</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 g tranexamic acid: 20</p> <p>1 g tranexamic acid: 11.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> <p>% occurrence heavy menstrual bleeding (PBAC score)</p> <p>Follow‐up: each cycle for 3 menstrual cycles</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 g tranexamic acid: 26.79</p> <p>1 g tranexamic acid: 45.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>d,g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>PBAC:</b> pictorial blood assessment chart; <b>RCT:</b> randomized controlled trial; vs: versus </p> <p><sup>a</sup>Downgraded one level due to unclear risk of selection and reporting bias. <br/><sup>b</sup>Downgraded two levels due to substantially wide confidence interval and effects measures from only one small trial. <br/><sup>c</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias as well as high risk of detection bias. <br/><sup>d</sup>Downgraded one level for imprecision as effect measures were from one trial. <br/><sup>e</sup>Downgraded two levels due to unclear risk of selection, performance, attrition and reporting bias as well as high risk of detection bias. <br/><sup>f</sup>Downgraded two levels due to unclear risk of selection, performance and reporting bias as well as high risk of other sources of bias (4 out of 10 women on intrauterine devices had prior to intervention, prolonged bleeding time, increased capillary fragility and/or a history of bleeding tendencies). <br/><sup>g</sup>Downgraded two levels due to unclear risk of selection and performance bias, high risk of detection bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) compared to placebo or active comparators (paracetamol, tranexamic acid) for the prevention of heavy menstrual bleeding associated with Cu IUD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Interventions (ulipristal acetate, tranexamic acid, mifepristone, naproxen) compared placebo or active comparators (mefenamic acid, vitamin B, estradiol) for the prevention of heavy menstrual bleeding associated with LNG IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ulipristal acetate vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage days bleeding or spotting</b> (questionnaire) </p> <p>Follow‐up: 1, 3 and 6 months after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean percentage days bleeding or spotting was 20.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.5% higher (1.48 higher to 17.52 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tranexamic acid vs mefenamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Median number of bleed days (diary)</p> <p>Follow‐up: 90 days of study assessment followed by 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid: 8</p> <p>Mefenamic acid: 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastrointestinal disorders, headache, breast tenderness, musculoskeletal disorders </p> <p>Follow‐up: 90 days of study assessment followed by 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>468 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>468 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00 (0.49 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mifepristone vs vitamin B</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual blood loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>% spotting and bleeding days</p> <p>Follow‐up: 1, 3 and 6 months after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mifepristone: fewer women reported bleeding or spotting. Fewer days with normal or heavy intensity bleeding </p> <p>Vitamin B: more bleeding or spotting days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> or <b>side effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naproxen vs estradiol</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual blood loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of bleeding</b> </p> <p>Median number of bleeding and spotting days (diary)</p> <p>Follow‐up: every 4 weeks for 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naproxen: 27.5</p> <p>Estradiol: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects:</b> gastroesophageal reflux </p> <p>Follow‐up: every 4 weeks for 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.22 (0.13 to 81.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>a,e</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level for imprecision as effects were measured from one trial.<br/><sup>b</sup>Downgraded one level due to unclear risk of performance bias.<br/><sup>c</sup>Downgraded one level due to high risk of detection bias<br/><sup>d</sup>Downgraded two levels due to high risk of detection bias and unclear risk of performance bias.<br/><sup>e</sup>Downgraded two levels due to high risk of performance bias and detection bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Interventions (ulipristal acetate, tranexamic acid, mifepristone, naproxen) compared placebo or active comparators (mefenamic acid, vitamin B, estradiol) for the prevention of heavy menstrual bleeding associated with LNG IUD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006034-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Interventions (ibuprofen, tolfenamic acid) compared to placebo for the prevention of pain associated with Cu IUD</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with comparisons</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ibuprofen vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in painful menstruation</p> <p>Follow‐up: end of 1st, 2nd and 3rd months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>200 per</b> 1000<br/>(27 to 691) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b><br/>(0.11 to 8.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Tolfenamic acid vs placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstruation "more painful than normal"</p> <p>Follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>310 per</b> 1000<br/>(217 to 476) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.71</b><br/>(0.44 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/><b>Very low</b><sup>c,d</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>vs:</b> versus </p> <p><sup>a</sup>Downgraded one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as effect measures were from one relatively small trial.<br/><sup>c</sup>Downgraded one level for imprecision as effect measures were from one trial.<br/><sup>d</sup>Downgraded two levels due to unclear risk of selection, performance, attrition and reporting bias as well as high risk of detection bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Interventions (ibuprofen, tolfenamic acid) compared to placebo for the prevention of pain associated with Cu IUD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006034-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of treatment trials interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Experimental Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>IUD type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Effectiveness trials</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0003" title="DaviesAJ , AndersonAB , TurnbullAC . Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology1981;57:74-8. ">Davies 1981</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 1250 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 500 mg on 1st day then 750 mg on subsequent days</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 cycles</p> <p>Each participant took 2 of the 3 treatments, each for 2 menstrual cycles.</p> <p>Each regimen was begun on the 1st day of menstrual bleeding and continued for a total of 5 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After every 2 menstrual cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage reduction in menstrual blood loss</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0004" title="FavaM , PeloggiaA , BaccaroLF , CastroS , CarvalhoN , BahamondesL . A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. International Journal of Gynaecology and Obstetrics2020;149:10-5. ">Fava 2020</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ulipristal acetate 5 mg/day for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 days, bleeding was assessed at 30 days, 60 days and 70 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bleeding days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0007" title="JafariA , AbediP , SayahiM , TorkashvandR . The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: a double-blind randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2014;19(3):180-6. [PMID: 24738933]">Jafari 2014</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral vitamin B1 100 mg/day during the 2nd, 3rd and 4th months following insertion of the IUD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo</p> <p>during the 2nd, 3rd and 4th months following insertion of the IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after completion of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of pads used</p> <p>Number of spotting days</p> <p>Duration of bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Pain trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0002" title="ButtramV , IzuA , HenzlMR . Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology1979;134:575-8. ">Buttram 1979</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen sodium 550 mg initially, then 275 mg every 6 hours as needed for uterine pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (lactose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown IUD type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall and daily pain relief score (6‐point Likert scale)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0009" title="LalosO , NilssonB . Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics1983;21:33-7. ">Lalos 1983</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 500 mg followed by 250 mg 2‐4 times a day, with a maximum of 1250 mg, taken at the first sign of menstrual distress. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo taken at the first sign of menstrual distress.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 cycles</p> <p>Participant took an intervention for 2 cycles then crossed over to the other intervention for 2 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 2nd and 4th menstrual cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain relief (5‐point Likert scale)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b><i>Comparative effectiveness trials</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Bleeding trials</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0001" title="AlanwarA , AbbasAM , HussainSH , ElhawwaryG , MansourDY , FaisalMM , et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. European Journal of Contraception &amp; Reproductive Health Care2018;23(5):365-70. [PMID: 30247074]">Alanwar 2018</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 500 mg, 1 tablet 6‐hourly during the 1st 3 days of menstrual bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral micronized flavonoid 500 mg, 1 tablet 6‐hourly during the 1st 3 days of menstrual bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> <p>Number of pads used/day</p> <p>Number of bleeding days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0008" title="KavianiM , RoozbehN , AzimaS , AmoiS . Comparing the effects of tranexamic acid and mefenamic acid in IUD-induced menorrhagia: randomized controlled trial. International Journal of Community Based Nursing and Midwifery2013;1(4):216-23. ">Kaviani 2013</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid, 250 mg; 1 capsule every 8 hours on the first 3 days of menstruation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid, 250 mg; 1 capsule every 8 hours on the first 3 days of menstruation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> <p>Number of bleeding days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0013" title="MercorioF , De SimoneR , Di CarloC , BifulcoG , TessitoreG , Di Spiezio SardoA , et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Human Reproduction2003;18:2319-22. ">Mercorio 2003</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desmopressin 300 mcg intranasal spray each morning for the first 5 days after start of menstruation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 1500 mg/day for the first 5 days after the start of menstruation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0016" title="SaharkhizN , EhdaeevandF , TavanaA , MajdfarZ , FallahianM . A comparative trial of the efficacy of mefenamic acid and tranexamic acid for treatment of menorrhagia induced by copper T-380A IUD. International Journal of Women's Health and Reproduction Sciences2017;5(3):175-80. ">Saharkhiz 2017</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 500 mg 3 times/day for 3‐5 days based on the duration of bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 500 mg 3 times/day for 3‐5 days based on the duration of bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volume of blood loss</p> <p>Duration of bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0019" title="YavarikiaP , ShahnaziM , Hadavand MirzaieS , JavadzadehY , LutfiR . Comparing the effect of mefenamic acid and Vitex agnus on intrauterine device induced bleeding. Journal of Caring Sciences2013;2(3):245-54. [PMID: 25276733]">Yavarikia 2013</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 250 mg 3 times/day from the 1st day of menstruation until day 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral Vitex agnus 3 times/day from the 1st day of menstruation until day 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown IUD type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0021" title="YlikorkalaO , ViinikkaL . Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology1983;90:78-83. ">Ylikorkala 1983</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 4.5 g/day for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral sodium diclofenac 150 mg on day 1 then 75 mg/day on days 2‐4</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 months</p> <p>Each participant received placebo for 1 month, 2 months of tranexamic acid, and 2 months of sodium diclofenac </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> <p>Duration of bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cu IUD:</b> copper intrauterine device; <b>HMB:</b> heavy menstrual bleeding; <b>IUD:</b> intrauterine device; <b>LNG IUD:</b> levonorgestrel intrauterine device; <b>PBAC:</b> pictorial blood loss assessment chart </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of treatment trials interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006034-tbl-0010"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of prevention trials interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Experimental intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>IUD type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Effectiveness trials</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0012" title="MakarainenL , YlikorkalaO . Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology1986;93:285-8. ">Makarainen 1986</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ibuprofen 1200 mg/day at the beginning of menstruation and to continue to end of bleeding for a maximum of 10 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo at the beginning of menstruation and to continue to end of bleeding for a maximum of 10 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> <p>Length of menstruation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0015" title="RoyS , Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding - effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstetrics and Gynecology1981;58:101-6. ">Roy 1981</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ibuprofen 1600 mg/day starting with bleeding and continuing until end of bleeding or maximum of 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo starting with bleeding and continuing until end of bleeding or maximum of 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> <p>Cu Lippes loop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> <p>Each participant had 1 month of observation, 1 month on ibuprofen or placebo, and 1 month crossed over to the alternative treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of month 1, 2, 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0018" title="WarnerP , GuttingerA , GlasierAF , LeeRJ , NickersonS , BrennerRM , et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Human Reproduction2010;25(2):345-53. [PMID: 19897857]">Warner 2010</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral CDB‐2914 50 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention taken for 3 consecutive days with separate treatments starting 21, 49 and 77 days after LNG IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1,3 and 6 months after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage days bleeding/ spotting, removal of LNG IUD within 6 months; the longest run of amenorrhoea in the 64 days after third treatment, side effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding and pain trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0006" title="HubacherD , ReyesV , LilloS , Pierre-LouisB , ZepedaA , ChenPL , et al. Preventing copper IUD removals due to side-effects among first time users: placebo-controlled randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction2006;21:1467-72. ">Hubacher 2006</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral ibuprofen 1200 mg/day to be taken with the first 6 menstruations after IUD insertion and for a maximum of 5 days at a time. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral placebo to be taken with the first 6 menstruations after IUD insertion and for a maximum of 5 days at a time. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 13, 26 and 52 weeks after IUD insertion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IUD removal within 12 months of insertion due to HMB/pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0020" title="YlikorkalaO , KauppilaA , SiljanderM . Anti-prostaglandin therapy in prevention of side effects of intrauterine devices. Lancet1978;2:393-5. ">Ylikorkala 1978</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tolfenamic acid 600 mg/day starting at IUD insertion and continuing for 7 days; this was to be repeated during the next 3 menstruations. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo starting at IUD insertion and continuing for 7 days; this was to be repeated during the next 3 menstruations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of pads used,</p> <p>menstruation more abundant than normal, clots,</p> <p>menstruation more painful than normal</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Comparative effectiveness trials</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleeding trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0005" title="HahnL , PetrusonB . The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. American Journal of Obstetrics and Gynecology1979;135:393-6. ">Hahn 1979</a> </p> <p>RCT with cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral aspirin 1500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral paracetamol 1500 mg/day</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> <p>Interventions taken on day 1 of menstruation and continued for the duration of bleeding.</p> <p>Each participant received each treatment in alternating order.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss (alkaline hematin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0010" title="LinX , GaoES , LiD , ZhangM , DouLX , YuanW . Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica2007;86(9):1126-9. [PMID: 17712656]">Lin 2007</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 2 g/day, taken for the 1st 5 days of 3 consecutive cycles after IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 1 g/day, taken for the 1st 5 days of 3 consecutive cycles after IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage occurrence of HMB by alkaline hematin and PBAC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0011" title="MaddenT , ProehlS , AllsworthJE , SecuraGM , PeipertJF . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal of Obstetrics and Gynecology2012;206(2):129.e1-8. [PMID: 22055339]">Madden 2012</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral naproxen 500 mg twice a day first 5 days of a 4‐week period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transdermal estradiol 0.1 mg on day after insertion of IUD, changing it weekly</p> <p>Oral placebo twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First 12 weeks of IUD use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone surveys at 4, 8, and 16 weeks and an in‐person follow‐up visit at 12</p> <p>weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median bleed days, patient satisfaction, continuation rates of IUD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0014" title="PapaikonomouK , Kopp KallnerH , SoderdahlF , Gemzell-DanielssonK . Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Human Reproduction2018;33(11):2002-9. ">Papaikonomou 2018</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral 50 mg mifepristone every other day starting on the 1st day of the menstrual cycle for the pre‐treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral vitamin B every other day starting on the 1st day of the menstrual cycle for the pre‐treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months (corresponding to 2 menstrual cycles i.e. 2 × 28 days) prior to insertion and until 3 days (± 2 days) following the LNG IUD insertion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for the first 3 months, 6 months post‐LNG IUD</p> <p>insertion and 12 months end‐of‐trial</p> <p>evaluation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding and spotting days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006034-bbs2-0017" title="SordalT , InkiP , DraebyJ , O'FlynnM , SchmelterT . Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstetrics and Gynecology2013;121(5):934-41. [PMID: 23635728]">Sordal 2013</a> </p> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral tranexamic acid 1500 mg/day, taken on the 1st day of a bleeding or spotting episode until bleeding or spotting stopped </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral mefenamic acid 1500 mg/day, taken on the 1st day of a bleeding or spotting episode until bleeding or spotting stopped </p> <p>Oral placebo (lactose and magnesium stearate), taken on the 1st day of a bleeding or spotting episode until bleeding or spotting stopped </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LNG IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median reduction of bleed days and length of bleed days, satisfaction with drug/placebo, occurrence of pain, number of days pain medication used to alleviate pain, adverse effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cu IUD:</b> copper intrauterine device; <b>HMB:</b> heavy menstrual bleeding; <b>IUD:</b> intrauterine device; <b>LNG IUD:</b> levonorgestrel intrauterine device; <b>PBAC:</b> pictorial blood loss assessment chart </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of prevention trials interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/full#CD006034-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin B1 vs placebo (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of pads/day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.00 [‐8.50, ‐5.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of spotting days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐1.94, ‐1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of bleeding days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐2.38, ‐1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin B1 vs placebo (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Naproxen vs placebo (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 "More" menstrual flow <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.72, 5.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Irregular flow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.36, 13.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Fluor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.12, 81.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Tender vagina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.12, 81.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.18, 25.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.12, 81.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Trembling legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.12, 81.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Blurry vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 17.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.8 Sore lips</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Naproxen vs placebo (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Volume of blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐64.26 [‐105.65, ‐22.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 PBAC score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.19 [‐25.24, 8.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Number of bleeding days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.27, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mefenamic acid vs tranexamic acid (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mefenamic acid vs desmopressin (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Mean reduction of PBAC score (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Side effects: headache and insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.00, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mefenamic acid vs desmopressin (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Menstrual blood loss (alkaline hematin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐42.70 [‐73.33, ‐12.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Duration of menstruation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.62, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [1.20, 18.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 PBAC score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.00 [‐39.84, ‐24.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Number of pads/day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.91, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Number of bleeding days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐1.93, ‐0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.30, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.18, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.25, 2.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Tranexamic acid vs flavonoids (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Tranexamic acid vs active comparators (mefenamic acid, flavonoids, diclofenac) (Cu IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Number of bleeding days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.14, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Tranexamic acid vs active comparators (mefenamic acid, flavonoids, diclofenac) (Cu IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Ulipristal acetate vs placebo (LNG IUD, treatment of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Duration of days until bleeding stops <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐9.07, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Total bleeding in 90 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.30 [‐26.76, 8.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Ulipristal acetate vs placebo (LNG IUD, treatment of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">High‐dose naproxen vs low‐dose naproxen (unknown IUD, treatment of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Blood loss reduction (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">High‐dose naproxen vs low‐dose naproxen (unknown IUD, treatment of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Mefenamic acid vs Vitex agnus (unknown IUD, treatment for HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 PBAC score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐13.77, 8.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.07, 5.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Mefenamic acid vs Vitex agnus (unknown IUD, treatment for HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for pain)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Pelvic pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 17.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Tranexamic acid vs sodium diclofenac (Cu IUD, treatment for pain)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Naproxen vs placebo (unknown IUD, treatment for pain)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Overall pain relief score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [0.91, 7.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Daily pain relief score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [0.27, 5.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.77, 10.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Need for analgesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.05, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Naproxen vs placebo (unknown IUD, treatment for pain)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Ibuprofen vs placebo (Cu IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Menstrual blood loss (alkaline hematin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.11 [‐36.04, 7.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Cu IUD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.47 [‐34.45, 15.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 Lippes Loop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.68 [‐75.44, 16.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Duration of bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.40, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Median menstrual blood loss (alkaline hematin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 Fincoid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 ML Cu 375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.50, 9.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 Eye and mouth swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.12, 82.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.2 Stomach cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.12, 82.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.3 Tired, irritable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.25, 11.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Ibuprofen vs placebo (Cu IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Tolfenamic vs placebo (Cu IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Number of pads/day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.57, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Menstruation "more abundant than normal" <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.34, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Clots in menstrual blood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.27, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Tolfenamic vs placebo (Cu IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Aspirin vs paracetamol (Cu IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Menstrual blood loss (alkaline hematin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐26.16, 25.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Aspirin vs paracetamol (Cu IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">2 g tranexamic vs 1 g tranexamic (Cu IUD, prevention HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Occurence of HMB (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 Alkaline hematin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.2 PBAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">2 g tranexamic vs 1 g tranexamic (Cu IUD, prevention HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Ulipristal acetate (CDB‐2914) vs placebo (LNG IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Percentage days bleeding or spotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.50 [1.48, 17.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Longest consecutive run of days without bleeding or spotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐6.93, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Ulipristal acetate (CDB‐2914) vs placebo (LNG IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Tranexamic acid vs mefenamic acid (LNG IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Median number of bleeding days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Tranexamic acid vs mefenamic acid (LNG IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Naproxen vs estradiol (LNG IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Median number of bleeding and spotting days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Satisfied with bleeding pattern at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.40, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [0.13, 81.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.1 Gastroesophageal reflux disease (GERD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [0.13, 81.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Naproxen vs estradiol (LNG IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Mifepristone vs vitamin B (LNG IUD, prevention of HMB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Percentage bleeding and spotting days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Mifepristone vs vitamin B (LNG IUD, prevention of HMB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Tolfenamic acid vs placebo (Cu IUD, prevention of pain)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Menstruation "more painful than normal" <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.44, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 9.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 Dyspepsia and diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.96 [0.52, 189.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.3 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Tolfenamic acid vs placebo (Cu IUD, prevention of pain)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Ibuprofen vs placebo (Cu IUD, prevention of pain)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Reduction in menstrual cramps <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 8.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Ibuprofen vs placebo (Cu IUD, prevention of pain)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006034-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Ibuprofen vs placebo (Cu IUD,prevention of bleed and pain, IUD removal)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 IUD removal by 26 weeks due to pain or increased blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.66, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 IUD removal due to pain or increased blood loss by 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.93, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Ibuprofen vs placebo (Cu IUD,prevention of bleed and pain, IUD removal)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006034.pub3/references#CD006034-tbl-0033">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006034.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006034-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006034-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006034-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006034-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD006034-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006034-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006034-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006034\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006034\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006034\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006034\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006034\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006034.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006034.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006034.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006034.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006034.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719371841"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006034.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719371845"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006034.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de722399af55b',t:'MTc0MDcxOTM3Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 